[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 148
1. Mao ZG, He DS, Zhou J, Yao B, Xiao WW, Chen CH, Zhu YH, Wang HJ: Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagn Pathol; 2010 Dec 07;5:79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of microRNAs in GH-secreting pituitary adenomas.
  • BACKGROUND: The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas;.
  • METHODS: Fifteen GH-secreting adenomas patients were treated with lanreotide for 4 months before surgery.
  • Patients with 50% reduction of GH secretion by lanreotide were considered as SSA responders, while patients with less than 50% of GH reduction were considered as SSA nonresponders.
  • We analyzed the miRNAs in 21 GH-secreting pituitary adenomas and 6 normal pituitaries by miRCURY™ LNA array and some differentially expressed miRNAs were validated by quantitative real-time PCR.
  • RESULTS: Fifty-two miRNAs were differentially expressed between GH-secreting pituitary adenomas and normal pituitaries.
  • Differential expression of 9 miRNAs was observed between micro- and macro-adenomas.
  • Seven miRNAs were differentially expressed between SSA responders or GH nonresponders.
  • Several identified miRNAs may be involved in cell proliferation, apoptosis, cancer development and progression.
  • CONCLUSIONS: Our results indicate that altered miRNAs expression is involved in GH-secreting pituitary adenomas transformation, which will shed light on the mechanisms for the treatment of acromegaly by SSA.
  • Identification and characterization of the targets of altered miRNAs genes may elucidate molecular mechanisms involved in the pathogenesis of pituitary adenoma.
  • [MeSH-major] Adenoma / genetics. Gene Expression Profiling. Growth Hormone-Secreting Pituitary Adenoma / genetics. MicroRNAs / analysis

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2008 Sep;15(3):721-43 [18753362.001]
  • [Cites] RNA. 2008 Jul;14(7):1433-42 [18492795.001]
  • [Cites] EMBO J. 2008 Oct 8;27(19):2616-27 [18756266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19300-5 [19033458.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):320-3 [18840638.001]
  • [Cites] Eur J Endocrinol. 2010 Apr;162(4):661-6 [20061334.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):901-6 [10706289.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):86-9 [11081512.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] Neurosurgery. 2001 Jun;48(6):1239-43; discussion 1244-5 [11383725.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Biochim Biophys Acta. 2003 Sep 22;1616(1):1-84 [14507421.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1577-85 [15070915.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):280-5 [15648093.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Dev Cell. 2006 Oct;11(4):441-50 [17011485.001]
  • [Cites] J Cell Physiol. 2007 Feb;210(2):370-7 [17111382.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2558-73 [17167139.001]
  • [Cites] Eur J Endocrinol. 2007 Jan;156(1):65-74 [17218727.001]
  • [Cites] Genes Dev. 2007 Apr 1;21(7):744-9 [17403776.001]
  • [Cites] Trends Genet. 2007 May;23(5):243-9 [17368621.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Aug;67(2):282-9 [17524029.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7713-22 [17699775.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):791-8 [17914108.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):32582-90 [17827156.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Mar;9(3):219-30 [18270516.001]
  • [Cites] Semin Cancer Biol. 2008 Apr;18(2):103-10 [18295504.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1203-10 [18198230.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1616-24 [18303074.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Nov;47(11):939-46 [18663744.001]
  • (PMID = 21138567.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00993356
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / MicroRNAs; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 51110-01-1 / Somatostatin
  • [Other-IDs] NLM/ PMC3017030
  •  go-up   go-down


2. Kim MS, Jang HD, Kim OL: Surgical results of growth hormone-secreting pituitary adenoma. J Korean Neurosurg Soc; 2009 May;45(5):271-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical results of growth hormone-secreting pituitary adenoma.
  • OBJECTIVE: We retrospectively analyzed the surgical outcomes of 42 patients with growth hormone (GH)-secreting pituitary adenoma to evaluate the clinical manifestations and to determine which preoperative factors that significantly influence the remission.
  • METHODS: Forty-two patients with GH-secreting pituitary adenoma underwent transsphenoidal surgery (TSS) between 1995 and 2007.
  • For comparable radiological criteria, we classified parasellar growth into five grades according to the Knosp classification.
  • There was a significant relationship between preoperative mean GH concentration and early postoperative outcome, with most patients in remission having a lower preoperative GH concentration.
  • CONCLUSION: TSS is thought to be an effective primary treatment for GH-secreting pituitary adenomas according to the most recent criteria of cure.
  • Because the remission rate in cases with cavernous sinus invasion is very low, early detection of the tumor before it extends into the cavernous sinus and a long-term endocrinological and radiological follow-up are necessary in order to improve the remission rate of acromegaly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Endocr Metab Disord. 2008 Mar;9(1):83-94 [18163213.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Dec;27(6):828-32 [17187024.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):230-9 [17047388.001]
  • [Cites] Surg Neurol. 2006 Jul;66(1):26-31; discussion 31 [16793431.001]
  • [Cites] Eur J Endocrinol. 2005 Mar;152(3):379-87 [15757854.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):171-90 [10207690.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26 [9768641.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2730-4 [9709939.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):1002-8 [9609294.001]
  • [Cites] Acta Neurochir (Wien). 1995;136(1-2):37-43 [8748825.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Jul;41(1):95-102 [8050136.001]
  • [Cites] Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8 [8232800.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):693-712 [1521519.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):271-5 [1727672.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):611-9 [14713271.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3567-72 [12915637.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):51-9; discussion 59-61 [12823873.001]
  • [Cites] J Neurosurg. 2003 May;98(5):1084-93 [12744370.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Apr;105(2):111-6 [12691803.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Jan;58(1):86-91 [12519417.001]
  • [Cites] Stereotact Funct Neurosurg. 2001;76(3-4):213-7 [12378100.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3142-7 [12107214.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4072-7 [11549628.001]
  • [Cites] Neurosurgery. 2001 Jun;48(6):1239-43; discussion 1244-5 [11383725.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:6-9 [11143264.001]
  • [Cites] Rev Endocr Metab Disord. 2008 Mar;9(1):71-81 [18163211.001]
  • (PMID = 19516943.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693785
  • [Keywords] NOTNLM ; Cavernous sinus / Growth hormone-secreting pituitary adenoma / Remission induction
  •  go-up   go-down


3. Sakai N, Kim K, Sanno N, Yoshida D, Teramoto A, Shibasaki T: Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation. Neurol Med Chir (Tokyo); 2008;48(11):481-7; discussion 487-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.
  • Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.
  • The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human GH-secreting pituitary adenoma cells.
  • Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH.
  • It has not been examined how gsp mutations influence GHRHR expression in GH-secreting adenomas.
  • We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in GH-secreting pituitary adenomas focusing on a gsp mutation.
  • Furthermore, we investigated the effect of GHRH on the expression of GHRHR mRNA in primary cultures of GH-secreting pituitary adenoma cells.
  • GHRHR mRNA expression levels were significantly elevated in gsp mutation-positive GH-secreting adenomas compared with those in gsp mutation-negative ones.
  • In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.
  • GHRH increased GHRHR mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.
  • These results suggest that gsp mutations up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.
  • [MeSH-major] Adenoma / genetics. GTP-Binding Protein alpha Subunits, Gs / genetics. Growth Hormone-Releasing Hormone / secretion. Mutation, Missense. Neoplasm Proteins / genetics. Nerve Tissue Proteins / genetics. Pituitary Neoplasms / genetics. Point Mutation. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Receptors, Neuropeptide / genetics. Receptors, Pituitary Hormone-Regulating Hormone / genetics
  • [MeSH-minor] Acromegaly / etiology. Acromegaly / surgery. Adult. Amino Acid Substitution. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cell Line, Tumor / secretion. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Pituitary adenoma, growth hormone-secreting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029774.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / somatotropin releasing hormone receptor; 9034-39-3 / Growth Hormone-Releasing Hormone; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


Advertisement
4. Bhatoe HS, Kotwal N, Badwal S: Clival pituitary adenoma with acromegaly: case report and review of literature. Skull Base; 2007 Jul;17(4):265-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clival pituitary adenoma with acromegaly: case report and review of literature.
  • The pituitary develops as a result of complex, intricate, and precise neuro-embryological events in the sixth to eighth weeks of gestation.
  • Some ectopic cell rests can become adenomatous.
  • Rarely, these cell rests in the clivus can be the site of formation of adenoma.
  • Our patient, a 35-year-old parous woman, was being treated for acromegaly, and imaging studies revealed a clival mass lesion.
  • Trans-sphenoidal excision was done and immunohistochemistry revealed the tumor to be a growth hormone-secreting tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 2002 Nov;144(11):1221-4 [12434179.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):262-72 [10483784.001]
  • [Cites] Neurosurgery. 1989 Feb;24(2):279-82 [2918981.001]
  • [Cites] J Clin Endocrinol Metab. 1986 May;62(5):1065-9 [3958123.001]
  • [Cites] Australas Radiol. 1970 Aug;14(3):241-7 [5477195.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):900-3 [7611536.001]
  • [Cites] Ultrastruct Pathol. 1993 Nov-Dec;17(6):637-42 [8122329.001]
  • [Cites] Otolaryngol Head Neck Surg. 1993 Feb;108(2):178-83 [8441545.001]
  • [Cites] Radiat Med. 1996 Jul-Aug;14(4):189-91 [8916261.001]
  • [Cites] Acta Chir Belg. 1998 Jan-Feb;98(1):10-3 [9538914.001]
  • (PMID = 18174927.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2039716
  • [Keywords] NOTNLM ; Acromegaly / clivus / pituitary tumor
  •  go-up   go-down


5. Pisarek H, Pawlikowski M, Kunert-Radek J, Winczyk K: Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? Endokrynol Pol; 2010 Mar-Apr;61(2):178-81
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
  • INTRODUCTION: The immunohistochemical examination of somatostatin receptor (SSTR) subtypes expression in different endocrine tumours, including pituitary adenomas, revealed membranous or cytoplasmic distribution of SSTR1-5.
  • In an earlier study a positive correlation between the summarized score of SSTR2A + SSTR2B expressions and growth hormone (GH) response to octreotide administration was found, independently of receptor distribution within the cell.
  • In this study we searched for the relationship between the GH inhibitory response to acute octreotide administration and SSTR2A, SSTR2B, and SSTR5 cellular localization.
  • The drop in GH was defined as the percentage of the basal value.
  • The pituitary adenomas from these patients were immunostained to determine the hormonal phenotype and expression of SSTR subtypes.
  • The drop in GH after octreotide administration varied between 57.1-96.7% (mean 82.1%).
  • Among the patients with the cytoplasmic localization of SSTR5, the decrease in GH was significantly higher (92.0 +/- 7.0%).
  • CONCLUSIONS: It seems that cytoplasmic localization of SSTR5, SSTR2A, and SSTR2B is connected with enhanced GH inhibition after octreotide administration.
  • As a consequence, the SSTR-immunopositivity in cell cytoplasm is increased.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / pathology. Octreotide / pharmacology. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / pathology. Receptors, Somatostatin / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / pharmacology. Chemotherapy, Adjuvant. Cytoplasm / pathology. Female. Growth Hormone / secretion. Humans. Immunohistochemistry. Male. Middle Aged. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464704.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


6. Kobayashi T, Mori Y, Uchiyama Y, Kida Y, Fujitani S: Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure? J Neurosurg; 2005 Jan;102(s_supplement):119-123

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure?
  • OBJECT: The authors conducted a study to determine the long-term results of gamma knife surgery for residual or recurrent growth hormine (GH)-producing pituitary adenomas and to compare the results with those after treatment of other pituitary adenomas.
  • Growth hormone normalization (GH < 1.0 ng/ml) was found in 4.8%, nearly normal (< 2.0 ng/ml) in 11.9%, significantly decreased (< 5.0 ng/ml) in 23.8%, decreased in 21.4%, unchanged in 21.4%, and increased in 16.7%.
  • Serum insulin-like growth factor (IGF)-1 was significantly decreased (IGF-1 < 400 ng/ml) in 40.7%, decreased in 29.6%, unchanged in 18.5%, and increased in 11.1%, which was almost parallel to the GH changes.
  • CONCLUSIONS: Gamma knife surgery was effective and safe for the control of tumors; however, normalization of GH and IGF-1 secretion was difficult to achieve in cases with large tumors and low-dose radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306435.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / growth hormone—producing pituitary adenoma / insulin-like growth factor
  •  go-up   go-down


7. Wasko R, Jaskuła M, Plewa R, Komarowska H, Poreba E, Goździcka-Józefiak A, Liebert W, Bednarek J, Sowiński J: The evaluation of ghrelin mRNA expression in human somatotroph adenomas. Neuro Endocrinol Lett; 2006 Feb-Apr;27(1-2):169-73
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evaluation of ghrelin mRNA expression in human somatotroph adenomas.
  • Ghrelin is one of the peptides involved into GH-release, binding to specific GHS receptors on hypothalamus and pituitary.
  • The ghrelin peptide and ghrelin mRNA have been detected in several regions of hypothalamus, in normal pituitary, as well as in various types of pituitary adenoma, with different levels of expression in different tumour types.
  • We decided to determine the expression of ghrelin in somatotroph adenomas.
  • Human pituitary somatotroph adenoma tissues were obtained at the time of transsphenoidal surgery from 3 acromegalic patients and studied for ghrelin mRNA expression.
  • We wished to determine the number of copies of ghrelin gene within the single cell.
  • [MeSH-major] Adenoma / metabolism. Human Growth Hormone / metabolism. Peptide Hormones / biosynthesis. Pituitary Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648773.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Actins; 0 / DNA, Complementary; 0 / Ghrelin; 0 / Peptide Hormones; 0 / RNA, Messenger; 12629-01-5 / Human Growth Hormone; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


8. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S: The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab; 2005 Nov;90(11):6290-5
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.
  • CONTEXT: Persistently elevated GH and IGF-I levels are associated with increased mortality.
  • OBJECTIVE: The objective of this study was to examine the significance of somatotroph adenoma type on response to SSA.
  • PATIENTS: Forty patients with acromegaly were studied.
  • MAIN OUTCOME MEASURES: Normalization of IGF-I levels and GH responses were the main outcome measures.
  • RESULTS: Univariate analysis revealed that responders were more likely to have densely granulated somatotroph adenomas (80% vs. 43.8%; P = 0.024), to be older (51.3 vs. 38.2 yr; P < 0.003), to have smaller tumors (stage < or =3; 78.6% vs. 35.7%; P = 0.022), to have lower baseline IGF-I (453 vs. 716 microg/liter; P < 0.001) and GH levels (2.7 vs. 7.8 microg/liter; P < 0.05), and to require a lower maximum dose of SSA (24 vs. 31 mg every 4 wk; P = 0.013).
  • Multivariate analysis confirmed that a densely granulated adenoma was the strongest predictor of complete response [adjusted odds ratio (OR), 58.41; 95% confidence interval (CI), 1.24-1000.00; P = 0.04] compared with other covariates, including older age at time of diagnosis (OR, 1.15/yr; 95% CI, 1.01-1.31; P = 0.03), and tumor stage of 3 or less (OR, 29.77; 95% CI, 1.01-885.45; P < 0.05).
  • CONCLUSIONS: Somatotroph tumor type represents a strong clinical predictor of response to SSA treatment and will help to identify patients who warrant more vigilant management of their disease.
  • [MeSH-major] Acromegaly / drug therapy. Adenoma / drug therapy. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / analysis. Male. Middle Aged. Multivariate Analysis. Phenotype. Retrospective Studies

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118335.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  •  go-up   go-down


9. Yasufuku-Takano J, Takano K, Morita K, Takakura K, Teramoto A, Fujita T: Does the prevalence of gsp mutations in GH-secreting pituitary adenomas differ geographically or racially? Prevalence of gsp mutations in Japanese patients revisited. Clin Endocrinol (Oxf); 2006 Jan;64(1):91-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the prevalence of gsp mutations in GH-secreting pituitary adenomas differ geographically or racially? Prevalence of gsp mutations in Japanese patients revisited.
  • OBJECTIVE: The prevalence of gsp mutations in GH-secreting pituitary adenomas was thought to differ geographically or racially, given its exceptionally lower incidence among Japanese patients (4.4-9.3%) compared to other regions (30-50%).
  • However, this notion is now being challenged after a recent paper reported a 53.3% incidence among Japanese with acromegaly.
  • PATIENTS: One hundred Japanese acromegaly patients with surgically confirmed GH-secreting pituitary adenomas were enrolled.
  • METHODS: mRNAs from primary cultured adenomas were used for reverse transcriptase-polymerase chain reaction and direct sequencing of the Gsalpha subunit.
  • Age at operation, sex ratio, basal serum GH and IGF-I levels were no different with or without the mutations.
  • In contrast, patients responded differently to most dynamic tests with statistical significance: serum GH levels in gsp-positive patients had blunted response to GHRH, were well suppressed by bromocriptine, and had higher rates of paradoxical response to TRH.
  • Octreotide suppressed GH levels strongly regardless of gsp status.
  • CONCLUSION: We conclude that the prevalence of gsp mutations in Japanese acromegaly patients is comparable to those of other reports from various regions.
  • Therefore, Japanese patients do not stand as an example for geographical or racial difference in the prevalence of gsp mutations in GH-secreting pituitary adenomas.
  • [MeSH-major] Adenoma / genetics. GTP-Binding Protein alpha Subunits, Gs / genetics. Pituitary Neoplasms / genetics. Point Mutation
  • [MeSH-minor] Acromegaly / ethnology. Acromegaly / metabolism. Adult. Asian Continental Ancestry Group. DNA Mutational Analysis. Female. Growth Hormone / blood. Growth Hormone / secretion. Growth Hormone-Releasing Hormone. Humans. Insulin-Like Growth Factor I / analysis. Japan. Male. Middle Aged. Prevalence. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402935.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


10. Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM: The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf); 2005 Feb;62(2):210-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
  • OBJECTIVE: To assess the long-term efficacy and safety of conventional radiotherapy (RT) in the control of acromegaly according to recent stringent criteria of cure.
  • PATIENTS AND METHODS: Forty-seven patients with active acromegaly were treated with conventional RT between 1982 and 1994.
  • All patients were first operated on and successively irradiated at a dose of 45-50 Gy in 25-28 fractions for persistent (n = 40) or recurrent (n = 7) disease.
  • MEASUREMENTS: Long-term GH/IGF-I secretion and local tumour control were evaluated regularly, and possible side-effects were searched for systematically, especially in terms of secondary endocrine dysfunction.
  • Biochemical cure of acromegaly was defined by glucose-suppressed plasma GH levels below 1 microg/l during an oral glucose tolerance test (OGTT) and normal age-corrected IGF-I values.
  • Suppression of GH during OGTT was seen in 9% of patients at 2 years, 29% at 5 years, 52% at 10 years, and 77% at 15 years.
  • Normalization of GH/IGF-I mainly depended on pre-RT levels.
  • CONCLUSION: Conventional RT is effective in the long-term control of GH-secreting pituitary adenomas, although with a high prevalence of progressive hypopituitarism.
  • [MeSH-major] Acromegaly / radiotherapy. Adenoma / radiotherapy. Adenoma / secretion. Growth Hormone / secretion. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / secretion
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Glucose Tolerance Test. Humans. Insulin-Like Growth Factor I / analysis. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670198.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


11. Zieliński G, Hendzel P, Szałański P, Gołowicz J, Gryszko L, Podgórski JK: [Severe cardiovascular complications due to the pituitary adenoma with acromegaly. An interdisciplinary approach to the treatment. A case report]. Neurol Neurochir Pol; 2006 Jul-Aug;40(4):354-60
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe cardiovascular complications due to the pituitary adenoma with acromegaly. An interdisciplinary approach to the treatment. A case report].
  • [Transliterated title] Ciezkie powikłania sercowo-naczyniowe w przebiegu guza przysadki powodujacego akromegalie. Propozycja równoczesnego wielospecjalistycznego leczenia. Opis przypadku.
  • Acromegaly reduces life expectancy and leads to 3-5-fold increase in mortality.
  • Successful therapy ought to normalize GH, IGF-I secretion, remove the adenoma mass and its local pressure effects and preserve pituitary functions intact to improve systemic morbidity and normalize mortality.
  • The primary therapy for most patients with acromegaly is still transsphenoidal adenomectomy.
  • The authors present a 64-year-old woman with diagnosed GH-secreting pituitary macroadenoma suffering from severe coronary heart disease and diabetes mellitus.
  • [MeSH-major] Acromegaly / surgery. Adenoma / surgery. Coronary Artery Disease / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Pituitary Neoplasms / surgery

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967359.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Koutourousiou M, Seretis A, Kontogeorgos G: Intra-sellar schwannoma co-existing with GH-secreting pituitary adenoma. Acta Neurochir (Wien); 2009 Dec;151(12):1693-7
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-sellar schwannoma co-existing with GH-secreting pituitary adenoma.
  • BACKGROUND: We present a unique example of an intra-sellar schwannoma co-existing with a growth hormone (GH)-secreting pituitary adenoma.
  • METHOD AND FINDINGS: The patient presented with acromegaly and magnetic resonance imaging (MRI) revealed an intra-sellar mass.
  • Histopathology demonstrated the presence of a GH-secreting adenoma as well as a schwannoma at the periphery of the adenoma.
  • After surgical excision, remission of the acromegaly occurred.
  • Follow-up monitoring showed no evidence of recurrence of the adenoma two years after surgery.
  • CONCLUSION: To the best of our knowledge, this is the first example of an intra-sellar schwannoma co-existing with a GH-secreting pituitary adenoma.
  • [MeSH-major] Adenoma / pathology. Neoplasms, Multiple Primary / pathology. Neurilemmoma / pathology. Pituitary Neoplasms / pathology. Sella Turcica / pathology
  • [MeSH-minor] Adult. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350200.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


13. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P: Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf); 2007 Aug;67(2):282-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
  • CONTEXT: The role of somatostatin analogues (SSTa) in the treatment of acromegaly.
  • OBJECTIVE: To evaluate the antihormonal and antitumour efficacy of long-term (up to 18 years) primary treatment with SSTa in patients with GH-secreting pituitary adenoma responsive to SSTa.
  • PATIENTS: Thirty-six acromegalic patients, aged 17-75 years (postoral glucose tolerance test GH > 1 microg/l, increased IGF-1 for age and sex), were monitored in a single centre and treated with SSTa as first-line therapy.
  • The mean pretreatment GH level was 13.5 +/- 3.1 microg/l, and IGF-1 (as a percentage of the value over the normal range) was 302 +/- 26%.
  • RESULTS: After 1 year, the mean GH and IGF-1 levels had reduced considerably (GH: 2.4 +/- 0.3 microg/l; IGF-1; 174 +/- 14%, P < 0.01), and they continued to decrease over 10 years, with a mean GH level of 1.6 +/- 0.1 microg/l and IGF-1 of 123 +/- 18% (P = 0.02).
  • GH < 2 microg/l, normal IGF-1, or both were observed in 25 (70%), 24 (67%) and 21 (58%) patients, respectively.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Growth Hormone / blood. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Insulin-Like Growth Factor I / analysis. Pituitary Neoplasms / drug therapy. Somatostatin / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Oct;90(10):5627-31 [16046586.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4483-8 [15899958.001]
  • [Cites] Trends Endocrinol Metab. 2005 Nov;16(9):407-13 [16213744.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):85-92 [16263832.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Feb;64(2):209-14 [16430722.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403 [16449332.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3779-85 [11061538.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4099-103 [11095439.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4596-602 [11134114.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):425-31 [11273062.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2779-86 [11397887.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4072-7 [11549628.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):99-104 [11788630.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71 [11849248.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8 [12213843.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4142-6 [12213862.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63 [12364434.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3090-8 [12843148.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3105-12 [12843150.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4709-19 [14557445.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5258-65 [14602759.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5414-21 [14602782.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):667-74 [14764779.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S101-6 [15135788.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):209-15 [15272916.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):113-8 [8027215.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Apr;18(4):765-72 [9127047.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):311-6 [9578821.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1962 Jun;87:989-1008 [13885978.001]
  • [Cites] Eur J Endocrinol. 2005 Mar;152(3):379-87 [15757854.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63 [15613435.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):61-6 [15762188.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):569-74 [15817912.001]
  • [Cites] Lancet. 2005 May 7-13;365(9471):1644-6 [15885297.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10 [15827109.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73 [15886238.001]
  • (PMID = 17524029.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Dopamine Agonists; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC1974833
  •  go-up   go-down


14. Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis CA, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH: A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep; 2007 Mar 28;1:9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report.
  • BACKGROUND: Germ-cell testicular cancer has not been definitively linked to any known hereditary cancer susceptibility disorder.
  • His evaluation as part of an etiologic study of familial testicular cancer revealed multiple colon polyps (adenomatous, hyperplastic, and hamartomatous) first found in his 50 s, multiple lipomas, multiple hyperpigmented skin lesions, left kidney cancer diagnosed at age 64, and a growth-hormone producing pituitary adenoma with associated acromegaly diagnosed at age 64.
  • Alternatively, this family's phenotype might represent a novel neoplasm susceptibility disorder.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):629-31 [15799199.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):662-6 [15185875.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):363-71 [15172357.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):984-92 [12569597.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Hum Mol Genet. 2006 Feb 1;15(3):443-51 [16407372.001]
  • (PMID = 17411461.001).
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N02CP11019
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1847830
  •  go-up   go-down


15. Picard C, Silvy M, Gerard C, Buffat C, Lavaque E, Figarella-Branger D, Dufour H, Gabert J, Beckers A, Brue T, Enjalbert A, Barlier A: Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. Int J Cancer; 2007 Sep 15;121(6):1245-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment.
  • Gs alpha is paternally silenced in normal pituitary, but Gs alpha imprinting relaxation is found in some tumoral tissue.
  • In addition, Gs alpha mRNA levels are high in some somatotroph adenomas not bearing the active Gs alpha mutant, the gsp oncogene.
  • We compared the expression and imprinting of 4 transcripts of GNAS locus (NESP55, XL alpha s, exon 1A, Gs alpha) of 60 somatotroph adenomas with those of 23 lactotroph adenomas.
  • [MeSH-major] Adenoma / genetics. Drug Resistance, Neoplasm / genetics. GTP-Binding Protein alpha Subunits, Gs / genetics. Genomic Imprinting. Growth Hormone-Secreting Pituitary Adenoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17514647.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / RNA, Messenger; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs; RWM8CCW8GP / Octreotide
  •  go-up   go-down


16. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol; 2005 Jul;153(1):135-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
  • OBJECTIVE: This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.
  • The effect of drugs was tested in cell cultures at various concentrations.
  • In 13 tumors, the maximal suppression of GH secretion produced by BIM-23A387 (30+/-3%) and BIM-23244 (28+/-3%) was greater than that produced by octreotide (23+/-3%).
  • In six out of 13 tumors, BIM-23A758, BIM-23A760 and BIM- 23A761 produced greater maximal suppression of GH secretion than octreotide (33+/-5, 38+/-2 and 41+/-2 vs 24+/-2%).
  • BIM-23A761 was more effective than BIM-23A387 in GH suppression (41+/-2 vs 32+/-4%).
  • CONCLUSIONS: Novel dopamine-somatostatin chimeric molecules with differing, enhanced activity at sstr2, sstr5 and DAD2, consistently produced significatly greater suppression of GH and PRL than either octreotide or single-receptor-interacting ligands in tumors from patients classified as only partially responsive to octreotide therapy.
  • The other mechanisms by which such molecules produce an enhanced inhibition of GH remain to be elucidated.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994755.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / BIM 23A760; 0 / BIM-23244; 0 / BIM-23A761; 0 / RNA, Messenger; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin; 0 / Recombinant Fusion Proteins; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide; VTD58H1Z2X / Dopamine
  •  go-up   go-down


17. Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T: Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage. Endocr J; 2006 Feb;53(1):125-32
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
  • We reviewed the cases of 32 patients with growth hormone (GH)-secreting macroadenoma who underwent short-term octreotide treatment before transsphenoidal surgery to determine which types of adenoma the preoperative treatment were sensitive and whether predictors of tumor shrinkage could be identified.
  • At a daily dose of 300 microg for 2-3 weeks, octreotide reduced serum GH and insulin-like growth factor-1 (IGF-1) levels to 31.9 % and 51.6% of pretreatment values, respectively, and led to a mean tumor volume of 68% of pretreatment volume in 52% of the patients.
  • Preoperative short-term octreotide treatment is effective for GH-secreting macroadeomas of Knosp grades 1-2 and a good response to both octreotide and bromocriptine challenge tests is a predictor of subsequent tumor shrinkage.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Growth Hormone-Secreting Pituitary Adenoma / pathology. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / pathology
  • [MeSH-minor] Acromegaly / etiology. Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / analysis. Magnetic Resonance Imaging. Male. Middle Aged. Patient Selection. Predictive Value of Tests. Preoperative Care / methods. Time Factors. Tumor Burden / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16543682.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


18. Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP: The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab; 2010 May;95(5):2334-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response.
  • CONTEXT: Appropriate cell-to-cell adhesion is fundamental for the epithelial phenotype of pituitary cells.
  • In somatotroph adenomas, a variable and reduced expression of E-cadherin has been demonstrated.
  • In addition, nuclear translocation of E-cadherin was found to correlate with pituitary tumor invasion.
  • OBJECTIVE: The objective was to examine the protein expression of E-cadherin in somatotroph pituitary adenomas in relation to adenoma size, invasiveness, and somatostatin analog (SMS) efficacy.
  • Adenoma E-cadherin protein expression was analyzed by Western blot (61 patients) and immunohistochemistry (IHC) (80 patients) with antibodies directed against both extracellular and intracellular domains (IHC).
  • RESULTS: Membranous E-cadherin was lost in several adenomas.
  • The E-cadherin level correlated positively to tumor reduction after SMS treatment, and adenomas with nuclear E-cadherin staining had lower IGF-I reduction and tumor shrinkage.
  • Preoperatively treated adenomas had reduced E-cadherin protein levels, but the IHC expression was unaltered.
  • CONCLUSION: Reduced E-cadherin expression may correlate to a dedifferentiated phenotype in the somatotroph pituitary adenomas.
  • [MeSH-major] Cadherins / genetics. Peptide Fragments / therapeutic use. Pituitary Neoplasms / genetics. Somatostatin / therapeutic use
  • [MeSH-minor] Acromegaly / complications. Acromegaly / surgery. Adult. Female. Growth Hormone / blood. Humans. Immunohistochemistry. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness


19. Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest; 2005;28(11 Suppl International):21-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
  • We report the comparative efficacy of a somatostatin receptor 1 and 5 subtypes (SSTR2 and SSTR5), and dopamine D2 (DAD2) compound, BIM-23A760, in suppressing GH secretion, in cell culture from human GH-secreting tumors, from patients partially responsive to long-term treatments with octreotide or lanreotide.
  • The SSTR2-selective analog, BIM-23197, the SSTR5-selective analog, BIM-23268, and the dopamine (DA) analog, BIM-53097, produced a mean maximal suppression of GH secretion (24 +/- 3, 20 +/- 3, and 20 +/- 3%, respectively) that was similar to that obtained with octreotide (23 +/- 3%).
  • Among a series of new chimeric compounds that bind the SSTR2, SSTR5, and DAD2 receptors with variable affinities, BIM-23A760 produced greater maximal suppression of GH secretion than octreotide (38 +/- 2 vs 24 +/- 2%; p<0.03).
  • In the presence of sulpride, the dose response inhibition of GH secretion by the trihybrid molecule, BIM-23A760, was partially reversed.
  • When SSTRs pan inhibitors such as BIM-23A779 (binding affinity for SSTR1, SSTR2, SSTR3, SSTR5, respectively: 2.5, 0.3, 0.6, 0.6 nmol/l) or SOM230 were tested for their suppressive effects on GH secretion, they were less potent than the previous dopastatin hybrid molecule.
  • After a brief exposure to a SSTR2-selective analog, BIM-23197, or to a DA analog, BIM-53097, the maximal GH suppression was achieved during 12 h.
  • Under exposure to BIM-23A760, in the same conditions, maximal suppression of GH secretion lasted for 24 h.
  • As compared to the dopastatin compound, the lower efficacy of the universal somatostatin ligands in the inhibition of GH secretion of GH-secreting tumors argues for the use of drugs targeted, according to specific receptors expression and functionality which may vary among the various classes of tumors.
  • [MeSH-major] Human Growth Hormone / secretion. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion. Receptors, Dopamine / metabolism. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Acromegaly / drug therapy. Adult. Female. Gene Expression. Humans. Male. Oligopeptides / pharmacology. Piperazines / pharmacology. Prolactin / secretion. RNA, Messenger / analysis. Receptors, Dopamine D2 / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625841.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BIM 23197; 0 / Oligopeptides; 0 / Piperazines; 0 / RNA, Messenger; 0 / Receptors, Dopamine; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


20. Wasko R, Jaskula M, Kotwicka M, Andrusiewicz M, Jankowska A, Liebert W, Sowinski J: The expression of ghrelin in somatotroph and other types of pituitary adenomas. Neuro Endocrinol Lett; 2008 Dec;29(6):929-38
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of ghrelin in somatotroph and other types of pituitary adenomas.
  • OBJECTIVES: It has been suggested that ghrelin synthesized locally in pituitary regulates the function and growth of pituitary cells in autocrine/paracrine way and might be an important factor of pituitary tumorogenesis.
  • The expression of ghrelin receptor in neoplastic cells of pituitary adenomas has also been demonstrated.
  • In vitro studies confirmed that ghrelin stimulates the proliferation of somatotroph cells in GH3 cell line.
  • This study showed the presence of ghrelin mRNA and its protein in different types of pituitary adenomas.
  • DESIGN: The samples of 37 pituitary adenomas were obtained during standard neurosurgical tumor removal.
  • The study tissues included 20 somatotroph tumors (15 patients treated and 5 patients untreated with octreotide LAR before the surgery), 12 nonfunctioning adenomas, 4 prolactinomas and 1 ACTH-secreting tumor.
  • Expression of ghrelin mRNA was studied in 28 pituitary adenomas by RT-PCR.
  • RESULTS: The presence of ghrelin gene transcripts was demonstrated in 10 out of 15 examined somatotroph tumors (obtained from patients treated with octreotide LAR before the surgery) and also in 2 out of 4 samples of prolactinomas, 7 out of 8 of nonfunctioning tumors and in 2 samples of normal pituitary.
  • Immunohistochemical analyses revealed the presence of the protein in all 5 examined somatotroph tumors obtained from patients not treated prior to the surgery and in 10 out of 15 tumors obtained from patients treated with octreotide LAR.
  • The peptide was detected also in 10 out of 12 examined nonfunctioning tumors and in 2 examined PRL-secreting tumors.
  • CONCLUSIONS: The study demonstrated that ghrelin gene is expressed in somatotroph adenomas, both treated and untreated with octreotide LAR before the surgery, and also in other types of pituitary adenomas (prolactinomas and nonfunctioning adenomas).
  • [MeSH-major] Adenoma / metabolism. Ghrelin / metabolism. Pituitary Neoplasms / metabolism. Somatotrophs / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112387.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Ghrelin; 0 / RNA, Messenger
  •  go-up   go-down


21. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD, degli Uberti EC: Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. J Mol Endocrinol; 2005 Oct;35(2):333-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
  • Dopamine (DA) and somatostatin (SRIF) receptor agonists inhibit growth hormone (GH) secretion by pituitary adenomas.
  • We investigated DA subtype 2 receptor (DR2) and SRIF receptor (sst) subtypes 2 and 5 expression in 25 GH-secreting pituitary adenomas and tested in primary culture the effects on GH and prolactin (PRL) secretion of sst agonists selectively interacting with sst2 (BIM-23120), sst5 (BIM-23206), and sst2 and sst5 (BIM-23244).
  • All adenomas expressed sst2; eight adenomas expressed both sst5 and DR2, eight sst5 but not DR2, and eight DR2 but not sst5.
  • GH secretion was inhibited by BIM-23120 in all samples, while it was reduced by BIM-23206 only in adenomas not expressing DR2.
  • BIM-23120's inhibitory effects correlated with sst2 and DR2 expression, whereas DR2 expression correlated inversely with BIM-23206 inhibitory effects on GH secretion.
  • In seven mixed GH-/PRL-secreting pituitary adenomas, PRL secretion was inhibited in sst5-expressing tumors by BIM-23206, but not by BIM-23120.
  • BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2. sst5 and DR2 expression correlated directly with BIM23206 inhibitory effects on PRL secretion.
  • Our results suggest that adenomas expressing DR2 are less likely to respond to clinically available SRIF analogs in terms of GH secretion inhibition.
  • Therefore, drugs interacting also with DR2 might better control secretion of pituitary adenomas.
  • [MeSH-major] Growth Hormone-Secreting Pituitary Adenoma / metabolism. Protein Isoforms / metabolism. Receptors, Dopamine / metabolism. Receptors, Somatostatin / metabolism. Somatostatin / analogs & derivatives
  • [MeSH-minor] Acromegaly / metabolism. Adult. Aged, 80 and over. Dopamine Agonists. Female. Human Growth Hormone / secretion. Humans. Male. Middle Aged. Prolactin / secretion. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216913.001).
  • [ISSN] 0952-5041
  • [Journal-full-title] Journal of molecular endocrinology
  • [ISO-abbreviation] J. Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Dopamine; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin
  •  go-up   go-down


22. Okinaga H, Takano K, Hayashi S, Yasufuku-Takano J, Teramoto A, Fujita T: Mechanisms of TRH-induced GH release (paradoxical response) in human somatotroph adenoma cells. Endocr J; 2005 Dec;52(6):763-7
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of TRH-induced GH release (paradoxical response) in human somatotroph adenoma cells.
  • The mechanisms of paradoxical TRH response in human somatotroph adenoma cells were investigated using intracellular calcium measurement and static incubation assay.
  • These calcium responses, especially the second phase, was responsible for the TRH-induced GH release.
  • [MeSH-major] Adenoma / secretion. Growth Hormone-Secreting Pituitary Adenoma / secretion. Human Growth Hormone / secretion. Thyrotropin-Releasing Hormone / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410670.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcium Channels; 12629-01-5 / Human Growth Hormone; 5Y5F15120W / Thyrotropin-Releasing Hormone; EC 2.7.11.13 / Protein Kinase C; SY7Q814VUP / Calcium
  •  go-up   go-down


23. Losa M, Gioia L, Picozzi P, Franzin A, Valle M, Giovanelli M, Mortini P: The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab; 2008 Jul;93(7):2546-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma.
  • CONTEXT: Single-session stereotactic radiotherapy (SR) may be a potential adjuvant treatment in acromegaly.
  • INTERVENTION: The patients were treated with SR for residual or recurrent GH-secreting adenoma.
  • MAIN OUTCOME MEASURE: Normalization of age- and sex-adjusted IGF-I levels together with a basal GH level below 2.5 microg/liter without concomitant GH-suppressive drugs was the goal of therapy.
  • Multivariate analysis showed that low basal GH and IGF-I levels were associated with a favorable outcome.
  • This may lead to reconsider the role of SR in the therapeutic algorithm of acromegaly.
  • [MeSH-major] Adenoma / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Radiosurgery
  • [MeSH-minor] Adult. Female. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / analysis. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Pituitary adenoma, growth hormone-secreting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Endocrinol Metab. 2008 Nov;4(11):592-3 [18762791.001]
  • (PMID = 18413424.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


24. Morita K, Takano K, Yasufuku-Takano J, Yamada S, Teramoto A, Takei M, Osamura RY, Sano T, Fujita T: Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas. Clin Endocrinol (Oxf); 2008 Mar;68(3):435-41
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
  • OBJECTIVE: Apart from the constitutively activating mutation of the G-protein alpha subunit (Gsalpha) (gsp mutation), factors involved in tumorigenesis or those in tumour behaviour remain elusive in sporadic GH-secreting pituitary adenomas.
  • Recently, the N-terminally truncated form of fibroblast growth factor receptor-4 (ptd-FGFR4) was identified in pituitary adenomas.
  • This aberrant receptor has transforming activity, and causes pituitary adenomas in transgenic mice.
  • MATERIALS AND METHODS: mRNA was extracted from excised adenomas of 45 Japanese acromegalic patients. ptd-FGFR4 expression and gsp mutations were determined by reverse transcription polymerase chain reaction (RT-PCR) and direct sequencing.
  • Preoperative clinical data were collected by reviewing medical charts and pituitary magnetic resonance imaging (MRI) scans.
  • The presence of ptd-FGFR4 did not correlate with age at operation, sex, preoperative serum GH or IGF-1 levels.
  • CONCLUSIONS: We found that ptd-FGFR4 expression and gsp mutations occur independently of each other, and that ptd-FGFR4 expression is associated with more invasive tumours in patients with GH-secreting pituitary adenomas.
  • [MeSH-major] GTP-Binding Protein alpha Subunits / genetics. Gene Expression. Growth Hormone-Secreting Pituitary Adenoma / genetics. Mutation. Neoplasm Invasiveness. Pituitary Neoplasms / genetics. Receptor, Fibroblast Growth Factor, Type 4 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070145.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GTP-Binding Protein alpha Subunits; 0 / Protein Isoforms; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 4
  •  go-up   go-down


25. Yin J, Su CB, Xu ZQ, Yang Y, Ma WB, Tao W, Yang Z, Xia XW: Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery. Chin Med Sci J; 2005 Mar;20(1):23-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
  • OBJECTIVE: To investigate whether somatostatin analog octreotide long acting release (LAR) shrinks growth hormone (GH) secreting adenomas, and improves the results of subsequent transsphenoidal surgery.
  • METHODS: Seventeen previously untreated active acromegalic patients with pituitary adenomas were treated with LAR (30 mg intramuscular injection every 28 days) for 3 months prior to transsphenoidal surgery.
  • Clinical reaction, mean GH secretion, and tumor volume were measured under basal conditions and after LAR treatment.
  • RESULTS: Presurgical treatment improved acromegaly symptoms and induced a significant reduction of GH under the 5 ng/mL limit in microadenoma (P < 0.05), while only 18.2% (2/11) in macroadenoma.
  • During operation, adenoma was soft in 15 cases, with the exception of 2 cases in which the soft tumor was divided by fibrous septa, but all tumor removal was smooth.
  • CONCLUSIONS: A short term administration of preoperative LAR may induce a significant decrease in GH-secretion level and adenoma volume.

  • Genetic Alliance. consumer health - Pituitary adenoma, growth hormone-secreting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844307.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


26. Tunici P, Yu JS: Pituitary adenoma stem cells. Methods Mol Biol; 2009;568:195-201
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenoma stem cells.
  • The identification of a subpopulation of brain tumor cells with potent tumorigenic capacity strengthens the cancer stem cell hypothesis of the origin of the tumors that has recently attracted the attention of many researchers.
  • These cells express stem cell markers, and when differentiated they express glial and neuronal markers.
  • More recently we have isolated tumor stem-like cells also from benign tumors like pituitary adenomas.
  • Cells derived from pituitary adenomas are able to grow as floating aggregates resembling the neurospheres (typical of normal stem cells) in a medium supplemented by growth factors (EGF and bFGF).
  • The immunocytochemical analysis revealed that pituitary tumor stem-like cells are positives for nestin and, when grown for ten days in differentiation medium they express GFAP, BIII tubulin, and S-100.
  • In vitro tumor stem-like cells derived from a patient with a somatotroph adenoma showed high production of growth hormone and prolactin, while cells derived from the same patient but grown in presence of fetal bovine serum showed no production of hormones.
  • [MeSH-major] Cell Culture Techniques / methods. Neoplastic Stem Cells / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Human Growth Hormone / metabolism. Humans. Immunohistochemistry. Prolactin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582428.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


27. Xu T, Ye F, Wang B, Tian C, Wang S, Shu K, Guo D, Lei T: Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation. Neuro Endocrinol Lett; 2010;31(1):147-54
Genetic Alliance. consumer health - Pituitary adenoma, growth hormone-secreting.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation.
  • OBJECTIVE: The purpose of this study was to investigate the relationship between the ghrelin or GHSR-1a mRNA levels and clinical characteristics and to confirm the effect of gsp mutations on ghrelin/GHSR-1a system in human GH-secreting pituitary adenomas.
  • The gsp mutations in 43 cases of human GH-secreting pituitary adenomas were detected using PCR-DNA direct sequencing analysis.
  • Clinical data were obtained from the medical records of 43 acromegalic patients who had GH and IGF-1 assays in the same laboratory.
  • The expression level of GHSR-1a mRNA was significantly higher in gsp positive adenomas than in negative adenomas (p<0.05).
  • Whereas, there was no significant difference in the expression of ghrelin mRNA between gsp mutation-positive and -negative adenomas (p>0.05).
  • Additionally there was a significant positve correlation between the ghrelin and GHSR-1a mRNA expression levels in gsp-positive (R=0.553, p=0.040) or -negative adenomas (R=0.489, p=0.007).
  • Gsp mutations may upregulate the expression of GHSR-1a mRNA and have no effect on ghrelin mRNA levels in human GH-secreting pituitary adenomas.
  • [MeSH-major] Adenoma / genetics. GTP-Binding Protein alpha Subunits / genetics. Growth Hormone-Secreting Pituitary Adenoma / genetics. Mutation. Receptors, Ghrelin / genetics
  • [MeSH-minor] Acromegaly / etiology. Acromegaly / genetics. Adult. Female. Ghrelin / genetics. Ghrelin / metabolism. Humans. Male. Middle Aged. RNA, Messenger / metabolism. Retrospective Studies. Tumor Burden. Up-Regulation. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150876.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / GTP-Binding Protein alpha Subunits; 0 / Ghrelin; 0 / RNA, Messenger; 0 / Receptors, Ghrelin
  •  go-up   go-down


28. Taguchi T, Takao T, Iwasaki Y, Oyama K, Yamada S, Inoue M, Terada Y: Diagnostic value of 18F-dihydroxyphenylalanine positron emission tomography for growth hormone-producing pituitary adenoma. Pituitary; 2010;13(1):78-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of 18F-dihydroxyphenylalanine positron emission tomography for growth hormone-producing pituitary adenoma.
  • A 55-year-old woman with signs of acromegaly was referred to our hospital.
  • Endocrinological examinations showed that she had high levels of growth hormone (GH; 5.54 ng ml(-1); normal range: 0.66-3.68 ng ml(-1)) and insulin-like growth factor-I (IGF-I; 508 ng ml(-1); normal range: 37-266 ng ml(-1)) levels, incomplete suppression of serum GH following a 75-gram oral glucose tolerance test (oGTT; trough GH 3.66 ng ml(-1)), and paradoxical GH responses to a TRH provocation test (peak GH 38.9 ng ml(-1)).
  • Dynamic magnetic resonance imaging (MRI) suggested the presence of an intrasellar mass lesion (5.9 x 2.8 mm) in the left part of her pituitary gland (Fig.
  • Subsequent histological analysis confirmed the diagnosis of a GH-producing pituitary adenoma.
  • After removal, serum IGF-I levels decreased to a normal range (178 ng ml(-1)), and serum GH was appropriately suppressed during oGTT (trough GH 0.30 ng ml(-1)), suggesting that complete resection was obtained [1].
  • PET scans are reported to be a valuable tool for the detection of pituitary adenomas [2-4].
  • This case clearly showed that FDG-PET is also useful for re-evaluation of the disease after surgery.
  • PET scans are recommended for patients with equivocal pituitary mass lesions on conventional MRI, and for follow-up examinations after surgery.
  • [MeSH-major] Dihydroxyphenylalanine. Fluorine Radioisotopes. Growth Hormone-Secreting Pituitary Adenoma / diagnosis. Positron-Emission Tomography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19915981.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 63-84-3 / Dihydroxyphenylalanine
  •  go-up   go-down


29. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA: Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab; 2007 Aug;92(8):3321-5
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Our objective was to evaluate the role of CDKN1B/p27(Kip1) in human tumor predisposition in patients clinically suspected of MEN1 but testing negative for MEN1 germline mutation as well as in familial and sporadic acromegaly/pituitary adenoma patients.
  • In addition, 19 familial and 50 sporadic acromegaly/pituitary adenoma patients from Europe and the United States were included in the study.
  • MAIN OUTCOME MEASURES: We analyzed germline CDKN1B/p27(Kip1) mutations in individuals with pituitary adenoma and MEN1-like features.
  • RESULTS: A heterozygous 19-bp duplication (c.59_77dup19) leading to a truncated protein product was identified in one Dutch patient with suspected MEN1 phenotype, pituitary adenoma, carcinoid tumor, and hyperparathyroidism (one of 36, 2.8%).
  • No mutations were detected in either familial or sporadic acromegaly/pituitary adenoma patients.
  • CONCLUSIONS: Our results support the previous finding that germline CDKN1B/p27(Kip1) mutations predispose to a human MEN1-like condition.
  • However, such mutations appear uncommon in suspected MEN1 cases and rare or nonexistent in familial or sporadic acromegaly/pituitary adenoma patients.

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519308.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF474465
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 9007-49-2 / DNA
  •  go-up   go-down


30. Campbell PG, Kenning E, Andrews DW, Yadla S, Rosen M, Evans JJ: Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus; 2010 Oct;29(4):E5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
  • OBJECT: Using strict biochemical remission criteria, the authors assessed surgical outcomes after endoscopic transsphenoidal resection of growth hormone (GH)-secreting pituitary adenomas and identified preoperative factors that significantly influence the rate of remission.
  • The authors reviewed cases in which an endoscopic resection of GH-secreting pituitary adenomas was performed.
  • The thresholds of an age-appropriate, normalized insulin-like growth factor-I concentration, a nadir GH level after oral glucose load of less than 1.0 μg/l, and a random GH value of less than 2.5 μg/l were required to establish biochemical cure postoperatively.
  • RESULTS: Overall, in 57.7% of patients undergoing a purely endoscopic transsphenoidal pituitary adenectomy for acromegaly, an endocrinological cure was achieved.
  • CONCLUSIONS: A purely endoscopic transsphenoidal approach to GH-secreting pituitary adenomas leads to similar outcome for noninvasive macroadenomas compared with traditional microsurgical techniques.
  • Furthermore, this approach may often provide maximal visualization of the tumor, the pituitary gland, and the surrounding neurovascular structures.
  • [MeSH-major] Acromegaly / surgery. Endoscopy / methods. Growth Hormone-Secreting Pituitary Adenoma / surgery. Human Growth Hormone / secretion
  • [MeSH-minor] Adenoma / surgery. Adult. Aged. Female. Humans. Insulin-Like Growth Factor I / analysis. Longitudinal Studies. Male. Microsurgery / methods. Middle Aged. Neoplasm Invasiveness. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Remission Induction. Sphenoid Bone. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887130.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


31. Kontogeorgos G, Mourouti G, Kyrodimou E, Liapi-Avgeri G, Parasi E: Ganglion cell containing pituitary adenomas: signs of neuronal differentiation in adenoma cells. Acta Neuropathol; 2006 Jul;112(1):21-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglion cell containing pituitary adenomas: signs of neuronal differentiation in adenoma cells.
  • Ganglion cell containing pituitary adenomas are rare.
  • Recently accumulated information suggests a common origin for their neuronal and pituitary constituents.
  • The objective of this study was to report the clinical and morphologic findings of pituitary gangliocytomas and study their immunoprofile using neuronal markers.
  • Seven cases of pituitary gangliocytomas retrieved from 1,322 sellar lesions were studied.
  • All tumors were removed from patients with mild acromegaly.
  • Histologically they were biphasic composed of pituitary adenoma and clusters of ganglion cells embedded in a variably dense neuropil substrate.
  • All adenomas belonged to the category of sparsely granulated somatotroph adenoma and were positive for growth hormone, whereas in five tumors, a few adenoma cells were also positive for prolactin.
  • Interestingly, all tumors contained varying numbers of adenoma cells with NFP-positive, dot-like areas of cytoplasmic reactivity, mostly tiny paranuclear, a finding not previously reported in human pituitary gangliocytomas.
  • The presence of NFP in pituitary adenomas indicates neuronal differentiation in adenoma cells, suggesting a common origin for neuronal and pituitary adenoma cell elements in gangliocytomas.
  • [MeSH-major] Adenoma / classification. Adenoma / pathology. Ganglioneuroma / classification. Ganglioneuroma / pathology. Pituitary Neoplasms / classification. Pituitary Neoplasms / pathology
  • [MeSH-minor] Acromegaly / etiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neurofilament Proteins / metabolism. Sella Turcica / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699777.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neurofilament Proteins
  •  go-up   go-down


32. Pawlikowski M, Pisarek H, Kunert-Radek J, Radek M: Somatostatin receptors in GH-secreting pituitary adenomas--their relationship to the response to octreotide. Endokrynol Pol; 2008 May-Jun;59(3):196-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin receptors in GH-secreting pituitary adenomas--their relationship to the response to octreotide.
  • Twenty pituitary adenomas, surgically removed from patients suffering from acromegaly, were studied.
  • The tumours were immunostained with anti-GH and anti-PRL antibodies and with antibodies raised against particular subtypes of somatostatin receptors (rsst1-5).
  • In 15 patients in whom the GH response to the acute administration of 200 ug octreotide was tested the correlation between the expression of rsst and the percentage of GH drop was estimated.
  • All the tumours were GH-immunopositive and in the majority (14/20) co-expression of PRL was also found.
  • All the adenomas examined expressed rsst2A (20/20) and rsst5 (12/12) receptor proteins.
  • The mixed (GH/PRL) adenomas showed a tendency to a higher expression of rsst2A + + rsst2B and a greater response to octreotide administration.
  • A significant positive correlation was found between rsst2A + rsst2B expressions and a drop in GH after octreotide.
  • To conclude, the GH-inhibiting effect of octreotide depends on the intensity of expression of both rsst2A and rsst2B.
  • Both isoforms of rsst2 mediate the same biological response (inhibition of GH secretion) in GH-secreting and GH/PRL-secreting adenomas.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / metabolism. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Growth Hormone-Secreting Pituitary Adenoma / metabolism. Octreotide / therapeutic use. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Acromegaly / etiology. Antineoplastic Agents / therapeutic use. Growth Hormone / drug effects. Growth Hormone / secretion. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18615392.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Somatostatin; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


33. Kobayashi T, Mori Y, Uchiyama Y, Kida Y, Fujitani S: Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure? J Neurosurg; 2005 Jan;102 Suppl:119-23
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure?
  • OBJECT: The authors conducted a study to determine the long-term results of gamma knife surgery for residual or recurrent growth hormine (GH)-producing pituitary adenomas and to compare the results with those after treatment of other pituitary adenomas.
  • Growth hormone normalization (GH < 1.0 ng/ml) was found in 4.8%, nearly normal (< 2.0 ng/ml) in 11.9%, significantly decreased (< 5.0 ng/ml) in 23.8%, decreased in 21.4%, unchanged in 21.4%, and increased in 16.7%.
  • Serum insulin-like growth factor (IGF)-1 was significantly decreased (IGF-1 < 400 ng/ml) in 40.7%, decreased in 29.6%, unchanged in 18.5%, and increased in 11.1%, which was almost parallel to the GH changes.
  • CONCLUSIONS: Gamma knife surgery was effective and safe for the control of tumors; however, normalization of GH and IGF-1 secretion was difficult to achieve in cases with large tumors and low-dose radiation.
  • [MeSH-major] Adenoma / secretion. Adenoma / surgery. Human Growth Hormone / secretion. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery. Radiosurgery / instrumentation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Outcome Assessment (Health Care). Pituitary ACTH Hypersecretion / pathology. Pituitary ACTH Hypersecretion / surgery. Prolactinoma / pathology. Prolactinoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662793.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


34. Guerrero CA, Krayenbühl N, Husain M, Krisht AF: Ectopic suprasellar growth hormone-secreting pituitary adenoma: case report. Neurosurgery; 2007 Oct;61(4):E879; discussion E879
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic suprasellar growth hormone-secreting pituitary adenoma: case report.
  • OBJECTIVE: Ectopic pituitary adenomas are rare.
  • We present an unusual case of an ectopic growth hormone-secreting pituitary adenoma in the suprasellar space.
  • CLINICAL PRESENTATION: A 31-year-old man presented with a history of chronic headache and typical clinical signs of acromegaly.
  • Magnetic resonance imaging scans revealed a suprasellar mass not arising from the normal looking pituitary gland.
  • Histological examination showed a growth hormone-secreting pituitary adenoma CONCLUSION: Although uncommon, growth hormone-secreting pituitary adenomas are encountered in the suprasellar region.
  • They should be added to the differential diagnosis of tumors in this location.
  • [MeSH-major] Adenoma / radiography. Choristoma. Growth Hormone-Secreting Pituitary Adenoma / radiography


35. Chang HP, Tseng YC, Chou TM: An enlarged sella turcica on cephalometric radiograph. Dentomaxillofac Radiol; 2005 Sep;34(5):308-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 28-year-old male presented to the Orthodontic clinic for correction of his anterior crossbite due to mandibular prognathism as a result of pituitary adenoma with acromegaly.
  • We discuss the radiographic diagnosis of an enlarged sella turcica in intrasellar tumours and also emphasise the dentist's important role in the initial diagnosis of pituitary adenoma cases.
  • [MeSH-major] Acromegaly / radiography. Cephalometry. Sella Turcica / radiography
  • [MeSH-minor] Adenoma / complications. Adult. Humans. Male. Malocclusion, Angle Class III / etiology. Malocclusion, Angle Class III / radiography. Patient Care Planning. Pituitary Neoplasms / complications. Prognathism / etiology. Prognathism / radiography. Radiographic Magnification. Radiography, Panoramic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120882.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


36. Lonser RR, Kindzelski BA, Mehta GU, Jane JA Jr, Oldfield EH: Acromegaly without imaging evidence of pituitary adenoma. J Clin Endocrinol Metab; 2010 Sep;95(9):4192-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly without imaging evidence of pituitary adenoma.
  • CONTEXT: GH-secreting pituitary adenomas are nearly always visible on conventional magnetic resonance (MR) imaging.
  • However, management and outcome of acromegalic patients lacking imaging evidence of GH-secreting pituitary adenomas are undefined.
  • OBJECTIVE: The aim was to evaluate surgical exploration for MR-invisible GH-secreting pituitary adenomas.
  • PATIENTS OR OTHER PARTICIPANTS: Consecutive acromegalic patients without imaging evidence of a pituitary adenoma on pre- and postcontrast, spin echo T1-weighted MR imaging and who lacked evidence of an ectopic (nonpituitary) source causing GH excess were included.
  • INTERVENTIONS: Surgical exploration with identification and resection of a pituitary adenoma was performed.
  • MAIN OUTCOME MEASURES: Laboratory values (GH, IGF-I), surgical findings, and clinical outcome were analyzed.
  • RESULTS: Six patients (three males, three females; 3% of all patients) with suspected GH-secreting adenomas did not demonstrate imaging evidence of pituitary adenoma on conventional MR imaging.
  • Three patients underwent a postcontrast, volumetric interpolated breath-hold examination MR-imaging sequence (1.2-mm slice thickness), which revealed a 4-mm pituitary adenoma not seen on the spin echo T1-weighted MR imaging in one patient.
  • A pituitary adenoma was identified and removed in all patients (mean diameter, 5.6 mm; range, 5 to 6.7 mm).
  • Histological analysis confirmed that the lesions were GH-secreting adenomas.
  • CONCLUSION: Acromegaly can be caused by GH-secreting pituitary adenomas that are not evident on conventional MR imaging.
  • Adenomas in some of these patients become evident using volumetric interpolated breath-hold examination MR imaging.
  • Surgical exploration of the pituitary gland in acromegalic patients with endocrine findings consistent with a GH-secreting adenoma but negative MR imaging can lead to identification and removal of an adenoma.

  • Genetic Alliance. consumer health - Acromegaly.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pituitary. 1999 Jun;2(1):29-41 [11081170.001]
  • [Cites] Pituitary. 2011 Dec;14(4):414-7 [19904612.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1565-9 [12679440.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):667-74 [14764779.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3099-102 [15240576.001]
  • [Cites] AJR Am J Roentgenol. 1990 May;154(5):1075-7 [2108545.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jan;184(1):313-9 [15615994.001]
  • [Cites] Eur Radiol. 2005 Mar;15(3):543-8 [15627195.001]
  • [Cites] Eur J Endocrinol. 2005 Mar;152(3):379-87 [15757854.001]
  • [Cites] J Neurosurg. 2006 Jan;104(1):7-19 [16509142.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2558-73 [17167139.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2035-41 [18381584.001]
  • [Cites] Orphanet J Rare Dis. 2008;3:17 [18578866.001]
  • [Cites] Endocr Pract. 2008 Sep;14(6):757-63 [18996799.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1509-17 [19208732.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):995-1002 [12063232.001]
  • (PMID = 20610592.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2936064
  •  go-up   go-down


37. Curto L, Squadrito S, Almoto B, Longo M, Granata F, Salpietro F, Torre ML, Marini F, Trimarchi F, Cannavo S: MRI finding of simultaneous coexistence of growth hormone-secreting pituitary adenoma with intracranial meningioma and carotid artery aneurysms: report of a case. Pituitary; 2007;10(3):299-305
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI finding of simultaneous coexistence of growth hormone-secreting pituitary adenoma with intracranial meningioma and carotid artery aneurysms: report of a case.
  • Coexistence of pituitary adenoma, intracranial meningioma and cerebral aneurysm has never been described.
  • We report on a patient with GH-secreting pituitary macroadenoma associated with a right frontal meningioma and with two intracavernous asymptomatic aneurisms.
  • A 61-year-old woman was referred to our Endocrine Unit 13 years after a right frontal craniotomy for a pituitary tumour.
  • Endocrine investigation showed high levels of IGF-1 (560 ng/ml) and increased basal serum GH (56 ng/ml) levels, not suppressed after OGTT.
  • MRI showed persistence of a homogeneously enhancing intra- and suprasellar lesion, compressing the visual pathways, with bilateral intracavernous invasion and simultaneous coexistence of a right intracavernous internal carotid artery (ICA) aneurysm in direct contact with the pituitary tumour.
  • Somatostatin analog treatment normalized GH and IGF-1 levels.
  • One year later, a new MRI confirmed the presence of the pituitary mass showing also a right intracranial frontal meningioma and a new ICA aneurysm on the left side.
  • Previous studies have suggested that prolonged GH hypersecretion could play a role in the genesis of intracranial aneurysms, inducing atherosclerotic and/or degenerative modification of the arterial walls.
  • Other aetiological factors include a mechanical effect due to a direct contact between adenoma and aneurysm.
  • Coexistence of pituitary adenoma and intracranial meningioma is a rare event, but also for this association it has been suggested that GH or other growth factors could play a role in appearance or in growth of meningioma.
  • In our case, meningioma appeared and grew, despite the effective treatment of acromegaly.
  • [MeSH-major] Carotid Artery Diseases / complications. Carotid Artery Diseases / diagnosis. Growth Hormone-Secreting Pituitary Adenoma / complications. Growth Hormone-Secreting Pituitary Adenoma / diagnosis. Intracranial Aneurysm / complications. Intracranial Aneurysm / diagnosis. Meningioma / complications. Meningioma / diagnosis. Pituitary Neoplasms / complications. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Cerebral Angiography. Female. Hormones / blood. Human Growth Hormone / secretion. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Middle Aged. Neurosurgical Procedures


38. Müssig K, Gallwitz B, Honegger J, Strasburger CJ, Bidlingmaier M, Machicao F, Bornemann A, Ranke MB, Häring HU, Petersenn S: Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma. Exp Clin Endocrinol Diabetes; 2007 Mar;115(3):198-202
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
  • BACKGROUND: Gigantism is rare with the majority of cases caused by a growth hormone (GH)-secreting pituitary adenoma.
  • Treatment options for GH-secreting pituitary adenomas have been widened with the availability of long-acting dopamine agonists, depot preparations of somatostatin analogues, and recently the GH receptor antagonist pegvisomant.
  • CASE REPORT: A 23-year-old male patient presented with continuous increase in height during the past 6 years due to a GH-secreting giant pituitary adenoma.
  • At immunohistochemistry, the tumour showed a marked expression of GH and a sparsely focal expression of prolactin.
  • Conversion from somatostatin analogue to pegvisomant normalized insulin-like-growth-factor-I (IGF-I) levels and markedly improved glucose tolerance.
  • CONCLUSION: Pegvisomant is a potent treatment option in patients with pituitary gigantism.
  • [MeSH-major] Adenoma / secretion. Adenoma / surgery. Gigantism / drug therapy. Gigantism / etiology. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / secretion. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery

  • Genetic Alliance. consumer health - Gigantism.
  • Genetic Alliance. consumer health - Pituitary adenoma, growth hormone-secreting.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427111.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / pegvisomant; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


39. Chesnokova V, Melmed S: Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):55-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary senescence: the evolving role of Pttg.
  • Despite the high prevalence of pituitary adenomas they are invariably benign, indicative of unique intrinsic mechanisms controlling pituitary cell proliferation.
  • Cellular senescence is characterized by a largely irreversible cell cycle arrest and constitutes a strong anti-proliferative response, which can be triggered by DNA damage, chromosomal instability and aneuploidy, loss of tumor suppressive signaling or oncogene activation.
  • Here we discuss prospective mechanisms underlying senescence-associated molecular pathways activated in benign pituitary adenomas.
  • Both deletion and over-expression of pituitary tumor transforming gene (Pttg) promote chromosomal instability and aneuploidy.
  • Abundant PTTG in GH-secreting pituitary adenomas also triggers p21-dependent senescence.
  • Pituitary p21 may therefore safeguard against further chromosomal instability by constraining pituitary tumor growth.
  • These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1729-33 [11748253.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):503-11 [11850775.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]
  • [Cites] Cell. 2003 Jun 13;113(6):703-16 [12809602.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):156-66 [9892021.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Exp Cell Res. 1961 Dec;25:585-621 [13905658.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):6-10 [15692944.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):660-5 [16079837.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Science. 2005 Aug 5;309(5736):886-7 [16081723.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] Trends Genet. 2008 Feb;24(2):77-85 [18192065.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell. 2008 Jun 13;133(6):958-61 [18555773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]
  • [Cites] Pituitary. 2009;12(1):40-50 [18270844.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):81-94 [19132009.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):677-8 [19223763.001]
  • [Cites] Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82 [19650784.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Cell. 2007 Jul 27;130(2):223-33 [17662938.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • (PMID = 20153804.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-11A1; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / R01 CA075979-11A1
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Other-IDs] NLM/ NIHMS185500; NLM/ PMC2906651
  •  go-up   go-down


40. Kawamata T, Kubo O, Hori T: Surgical removal of growth hormone-secreting pituitary adenomas with intensive microsurgical pseudocapsule resection results in complete remission of acromegaly. Neurosurg Rev; 2005 Jul;28(3):201-8
MedlinePlus Health Information. consumer health - Brain Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical removal of growth hormone-secreting pituitary adenomas with intensive microsurgical pseudocapsule resection results in complete remission of acromegaly.
  • Although some investigators recommended surgical removal of the borders between pituitary adenoma and the surrounding normal pituitary gland, there is so far little documentation of how intensive dissection of the border zone affects the actual clinical remission rate of pituitary adenomas.
  • We investigated the precise histological characteristics of the boundary, using surgical specimens from patients who underwent intensive resection of "microsurgical pseudocapsule" of growth hormone (GH)-secreting pituitary adenomas.
  • Furthermore, we compared the remission rate of acromegaly between subjects with (Group 1) and without (Group 2) intensive resection of microsurgical pseudocapsule in order to correlate the histological complete resection and endocrinological remission.
  • Histologically, most adenomas were in direct contact with normal pituitary gland that formed an increased fibrous component facing the adenoma, without a true histological pseudocapsule.
  • It was impossible to dissect the tumor at exactly the tumor--normal pituitary interface for the whole extent of the pituitary adenoma during surgery, and complete removal of the tumor inevitably included a portion of normal tissue (microsurgical pseudocapsule).
  • The biochemical remission rate was significantly higher in Group 1 than in Group 2 (90.0 vs 61.1%), and Group 1 showed no additional postoperative pituitary hypofunction.
  • The present results suggested that intensive resection of the microsurgical pseudocapsule is essential to accomplish histological and endocrinological total resection of the GH-secreting pituitary adenomas for remission of acromegaly.

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765245.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Takano K, Yasufuku-Takano J, Morita K, Mori S, Takei M, Osamura RY, Teramoto A, Fujita T: Evidence that PKA activity is constitutively activated in human GH-secreting adenoma cells in a patient with Carney complex harbouring a PRKAR1A mutation. Clin Endocrinol (Oxf); 2009 May;70(5):769-75
Genetic Alliance. consumer health - Carney Complex.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence that PKA activity is constitutively activated in human GH-secreting adenoma cells in a patient with Carney complex harbouring a PRKAR1A mutation.
  • CONTEXT: The GHRH-protein kinase A (PKA) signalling pathway is essential for cell proliferation and GH synthesis/secretion in somatotrophs.
  • The basal PKA activity of somatotroph adenoma cells from CNC has not been evaluated because of a limited amount of available tissue.
  • Primary cultured adenoma cells were subjected to electrophysiological experiments to evaluate PKA signalling in individual cells.
  • RESULTS: GHRH did not increase the nonselective cation current or the voltage-gated calcium current in these adenoma cells, in contrast to nonadenomatous somatotroph cells in which these currents increase through the PKA pathway.
  • Application of a PKA inhibitor inhibited the basal currents in these adenoma cells, results that were not observed in nonadenomatous somatotrophs.
  • CONCLUSIONS: The results demonstrate that PKA is activated at the basal state in these adenoma cells.
  • The data also show that both the nonselective cation current and the voltage-gated calcium current, vital regulators of GH secretion downstream of PKA, are maximally increased in these cells.
  • These maximally increased currents probably account for the excessive GH secretion.
  • [MeSH-major] Cyclic AMP-Dependent Protein Kinase RIalpha Subunit / genetics. Cyclic AMP-Dependent Protein Kinases / metabolism. Growth Hormone-Secreting Pituitary Adenoma / enzymology. Growth Hormone-Secreting Pituitary Adenoma / genetics. Lentigo / enzymology. Lentigo / genetics. Multiple Endocrine Neoplasia / enzymology. Multiple Endocrine Neoplasia / genetics. Mutation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178533.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / Codon, Nonsense; 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / DNA, Neoplasm; 0 / PRKAR1A protein, human; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  •  go-up   go-down


42. Stapleton CJ, Liu CY, Weiss MH: The role of stereotactic radiosurgery in the multimodal management of growth hormone-secreting pituitary adenomas. Neurosurg Focus; 2010 Oct;29(4):E11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of stereotactic radiosurgery in the multimodal management of growth hormone-secreting pituitary adenomas.
  • Growth hormone (GH)-secreting pituitary adenomas represent a common source of GH excess in patients with acromegaly.
  • Whereas surgical extirpation of the culprit lesion is considered first-line treatment, as many as 19% of patients develop recurrent symptoms due to regrowth of previously resected adenomatous tissue or to continued growth of the surgically inaccessible tumor.
  • Although medical therapies that suppress GH production can be effective in the management of primary and recurrent acromegaly, these therapies are not curative, and lifelong treatment is required for hormonal control.
  • The authors reviewed the growing body of literature concerning the role of radiosurgical procedures in the treatment armamentarium of acromegaly, and identified more than 1350 patients across 45 case series.
  • In this review, the authors report that radiosurgery offers true hormonal normalization in 17% to 82% of patients and tumor growth control in 37% to 100% of cases across all series, while minimizing adverse complications.
  • As a result, stereotactic radiosurgery represents a safe and effective treatment option in the multimodal management of primary or recurrent acromegaly secondary to GH-secreting pituitary adenomas.
  • [MeSH-major] Acromegaly / surgery. Adenoma / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Radiosurgery / methods. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Combined Modality Therapy. Human Growth Hormone / antagonists & inhibitors. Human Growth Hormone / secretion. Humans. Pituitary Neoplasms / blood. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Treatment Outcome. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887121.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


43. Bush ZM, Vance ML: Management of acromegaly: is there a role for primary medical therapy? Rev Endocr Metab Disord; 2008 Mar;9(1):83-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of acromegaly: is there a role for primary medical therapy?
  • Acromegaly is a chronic, debilitating disease caused by chronic growth hormone (GH) hypersecretion which results in chronic medical comorbidities, poor quality of life and high mortality rates.
  • Over 95% of acromegaly is caused by a somatotroph adenoma of the pituitary, and the first-line treatment is generally transsphenoidal surgery, which can be curative in 50-60% of patients.
  • Nonetheless, high rates of persistent acromegaly following surgery and the limited efficacy of radiation therapy necessitate chronic medical treatment for many patients.
  • Cabergoline, a dopamine agonist, offers a lower-cost option and may be effective in patients with a pituitary tumor that co-secretes GH and prolactin.
  • Pegvisomant is a GH receptor antagonist that produces exceptional biochemical response rates but lacks any direct effects on the tumor, which may limit its effectiveness as life-long monotherapy.
  • While medical treatment options for acromegaly have significantly improved over the last 30 years, limitations remain, and a multi-specialty team approach is necessary for the effective long-term management of patients with acromegaly.
  • [MeSH-major] Acromegaly / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Dopamine Agonists / therapeutic use. Humans. Neurosurgical Procedures / methods. Radiotherapy / methods. Receptors, Somatotropin / antagonists & inhibitors. Somatostatin / analogs & derivatives

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18163213.001).
  • [ISSN] 1389-9155
  • [Journal-full-title] Reviews in endocrine & metabolic disorders
  • [ISO-abbreviation] Rev Endocr Metab Disord
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK007646
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Receptors, Somatotropin; 51110-01-1 / Somatostatin
  • [Number-of-references] 88
  •  go-up   go-down


44. Andrioli M, Pecori Giraldi F, Losa M, Terreni M, Invitti C, Cavagnini F: Cushing's disease due to double pituitary ACTH-secreting adenomas: the first case report. Endocr J; 2010;57(9):833-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's disease due to double pituitary ACTH-secreting adenomas: the first case report.
  • Double pituitary adenomas are rare occurrences in autoptical, surgical and neuroradiological series and are mostly due to non-functioning pituitary adenomas, GH-secreting and prolactin-secreting adenomas.
  • ACTH secreting tumours are more rare and, to our knowledge, two distinct ACTH-producing adenomas within the same pituitary have never been reported.
  • We herewith describe a 56 year old woman with Cushing' s disease due to two clearly distinct ACTH-secreting pituitary adenomas.
  • She presented with signs and symptoms of hypercortisolism and hormonal testing was indicative for pituitary-dependent Cushing' s syndrome.
  • Sellar MRI visualized an asymmetric pituitary gland with suspect lesions in both the right and the left pituitary lobes.
  • Pathology confirmed the existence of two distinct adenomas located in different sites in the gland.
  • Our case indicates that double ACTH-secreting pituitary adenomas may occur in patients with Cushing' s disease.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / pathology. Adenoma / pathology. Neoplasms, Multiple Primary / pathology. Pituitary ACTH Hypersecretion / etiology
  • [MeSH-minor] Cushing Syndrome / etiology. Female. Humans. Middle Aged. Pituitary Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20595779.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


45. Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A, Colao A: Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab; 2010 Jan;95(1):13-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation.
  • CONTEXT: Mixed PRL- and GH-secreting pituitary adenomas are relatively common because somatotrophs and lactotrophs share the common somato-mammotroph progenitor lineage.
  • Conversely, the occurrence of a prolactinoma evolving into clinically and biochemically active acromegaly is a rare phenomenon.
  • OBJECTIVE AND RESULTS: We report a patient with a prolactinoma who after 15 yr of disease control by bromocriptine became resistant to dopaminergic drugs and due to the rapid tumor growth was submitted to four neurosurgeries and two stereotactic radiotherapies in the subsequent 5 yr.
  • Unexpectedly, in the last 1.5 yr, after the fourth neurosurgery and second gamma-knife, she complained of signs and symptoms of acromegaly that was biochemically confirmed.
  • Although samples from the initial surgery were positive for prolactin and negative for GH, about 10% of GH-positive cells were detected in tissue from the last surgery, consistent with the observed clinical shift to acromegaly.
  • CONCLUSIONS: These observations suggest that 1)treatment of prolactinomas resistant to dopaminergic drugs is still a challenge, and 2) the appearance of gsp oncogene in a prolactinoma evolving into acromegaly might be the underlying mechanism of this rare transition, further confirming that this mutational change is associated with somatotroph growth and transformation.
  • [MeSH-major] GTP-Binding Protein alpha Subunits, Gs / genetics. Growth Hormone-Secreting Pituitary Adenoma / genetics. Growth Hormone-Secreting Pituitary Adenoma / pathology. Pituitary Neoplasms / pathology. Prolactinoma / pathology
  • [MeSH-minor] DNA Mutational Analysis. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Mutation / physiology. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890024.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.- / GNAS protein, human; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


46. Schindler K, Christ ER, Mindermann T, Wieser HG: Transient MR changes and symptomatic epilepsy following gamma knife treatment of a residual GH-secreting pituitary adenoma in the cavernous sinus. Acta Neurochir (Wien); 2006 Aug;148(8):903-8; discussion 908
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient MR changes and symptomatic epilepsy following gamma knife treatment of a residual GH-secreting pituitary adenoma in the cavernous sinus.
  • OBJECTIVE: To report a rare side effect of gamma knife treatment of pituitary macroadenoma.
  • CASE REPORT: In a forty-one-year old female patient acromegaly was diagnosed due to a growth hormone secreting pituitary macroadenoma.
  • Following transsphenoidal surgery the patient underwent gamma knife treatment for persistent uncontrolled acromegaly activity of residual tumor, infiltrating the left cavernous sinus.
  • CONCLUSION: Gamma knife surgery of a pituitary adenoma may cause radiation induced MR changes of the mesial temporal lobe mimicking glioma or radionecrosis and cause symptomatic epileptic seizures.
  • [MeSH-major] Adenoma / surgery. Brain Injuries / etiology. Epilepsy / etiology. Growth Hormone-Secreting Pituitary Adenoma / surgery. Radiation Injuries / etiology. Radiosurgery / adverse effects
  • [MeSH-minor] Acromegaly / etiology. Acromegaly / surgery. Adult. Cavernous Sinus / pathology. Cavernous Sinus / physiopathology. Cavernous Sinus / surgery. Female. Humans. Magnetic Resonance Imaging. Necrosis / diagnosis. Necrosis / etiology. Necrosis / physiopathology. Neoplasm Recurrence, Local / surgery. Pituitary Gland / pathology. Pituitary Gland / physiopathology. Pituitary Gland / surgery. Positron-Emission Tomography. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Temporal Lobe / pathology. Temporal Lobe / radiation effects. Temporal Lobe / radionuclide imaging

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761113.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


47. Lee YH, Noh TW, Lee MK, Jameson JL, Lee EJ: Absence of activating mutations of CXCR4 in pituitary tumours. Clin Endocrinol (Oxf); 2010 Feb;72(2):209-13
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of activating mutations of CXCR4 in pituitary tumours.
  • OBJECTIVE: Mutations of the gsp oncogene are responsible for 30-40% of GH-producing pituitary adenomas and 10% of nonfunctioning pituitary adenomas (NFPAs).
  • However, the pathogenetic mechanism of the remaining pituitary tumours still remains to be identified.
  • Recently, the interaction between the chemokine stromal cell-derived factor 1 and its receptor CXCR4 was found to play an important role in GH production and cell proliferation in various pituitary adenoma cell lines.
  • As CXCR4 is a Gi-coupled chemokine receptor, its constitutive activating mutations may be involved in pituitary tumour formation by cyclic adenosine monophosphate (cAMP)-independent, ERK-related pathways.
  • PATIENTS AND METHODS: We investigated whether somatic activating-mutations of CXCR4 might be a possible tumourigenic mechanism for gsp-negative GH-secreting pituitary adenomas and NFPAs.
  • Direct sequencing of polymerase chain reaction-amplified products for coding exons of CXCR4 were performed using genomic deoxyribonucleic acid samples from 37 GH-producing pituitary tumour tissues that were negative for the gsp mutation and 14 CXCR4 expressing NFPAs.
  • RESULTS: Immunohistochemical analyses and double immunofluorescent staining of sectioned paraffin-embedded pituitary tissues revealed that CXCR4 is highly expressed in GH-producing pituitary adenomas and NFPAs.
  • Direct sequencing showed that two synonymous mutations in exon 2 (87 C > T and 414 C > T) were detected in 4 out of 51 pituitary tumours.
  • CONCLUSION: Our results indicate that an activating mutation of the CXCR4 may not be a common pathogenetic mechanism in GH-producing pituitary tumours and NFPAs.
  • [MeSH-major] Pituitary Neoplasms / genetics. Pituitary Neoplasms / metabolism. Receptors, CXCR4 / genetics. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Growth Hormone-Secreting Pituitary Adenoma / genetics. Growth Hormone-Secreting Pituitary Adenoma / metabolism. Humans. Immunohistochemistry. Mutation. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473177.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, CXCR4
  •  go-up   go-down


48. Mendoza V, Sosa E, Espinosa-de-Los-Monteros AL, Salcedo M, Guinto G, Cheng S, Sandoval C, Mercado M: GSPalpha mutations in Mexican patients with acromegaly: potential impact on long term prognosis. Growth Horm IGF Res; 2005 Feb;15(1):28-32
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSPalpha mutations in Mexican patients with acromegaly: potential impact on long term prognosis.
  • OBJECTIVE: The frequency of activating mutations of the GSPalpha gene as the etiology of GH-secreting pituitary adenomas has been the subject of important ethnogenetic variability.
  • Whereas up to 40% of Caucasian patients with acromegaly have tumors which harbor these somatic mutations, their prevalence among Asian populations is much lower.
  • In the present study, we investigated the prevalence of GSPalpha mutations in GH-secreting tumors obtained from a genetically homogenous population of Mexican patients with acromegaly.
  • We also sought to establish whether or not the presence of these mutations correlates in any way with the clinical or biochemical characteristics of the disease.
  • STUDY DESIGN AND METHODS: Fifty eight GH-secreting pituitary adenomas were examined for the presence of point mutations in either codon 201 or 227 of the GSPalpha gene, using PCR and direct sequencing of DNA extracted from either fresh or paraffin-embedded tissues.
  • Patients were prospectively followed clinically and biochemically for up to nine years after pituitary surgery.
  • The frequency and severity of the different clinical features of acromegaly did not differ between patients with and without GSPalpha mutations.
  • Patients with and without mutations had pre-operative GH and IGF-I elevations of similar magnitude, and although microadenomas appeared to be more frequent among patients with GSPalpha mutations, this did not reach statistical significance.
  • Upon short-term follow-up, biochemical cure (normal age- and gender-adjusted IGF-I and post-glucose GH below 1 ng/mL) was similarly achieved in both groups.
  • After 3-9 years of post-operative follow up however, a significantly greater proportion of patients with the mutation achieved a "safe" basal GH value (100% vs 33%, p=0.001) as well a lower nadir post-glucose GH (0.53+/-0.5 vs 2.9+/-6.2 ng/mL, p=0.04) although the rate of IGF-1 normalization did not differ between the 2 groups.
  • CONCLUSIONS: Our results show that the prevalence of GSPalpha mutations in Mexican patients with acromegaly is intermediate between that found in Asian and Caucasian populations.
  • In this well-defined genetic population the presence of codon 201 mutations appeared to be associated with a greater probability of achieving a "safe" GH value upon long-term follow-up.
  • [MeSH-major] Acromegaly / genetics. Adenoma / genetics. GTP-Binding Protein alpha Subunits, Gs / genetics. GTP-Binding Protein alpha Subunits, Gs / physiology. Mutation. Pituitary Neoplasms / genetics
  • [MeSH-minor] Adult. Codon. DNA Primers / chemistry. Exons. Female. Growth Hormone / metabolism. Heterozygote. Humans. Male. Mexico. Middle Aged. Point Mutation. Sex Factors. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701569.001).
  • [ISSN] 1096-6374
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Codon; 0 / DNA Primers; 9002-72-6 / Growth Hormone; EC 3.6.1.- / GNAS protein, human; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


49. Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maira G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L: Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab; 2008 Jul;93(7):2746-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.
  • OBJECTIVE: The aim of the study was to evaluate the Ki-67 index prognostic relevance in a group of acromegalic patients who underwent transsphenoidal surgery for a GH-secreting pituitary adenoma.
  • The Ki-67 index was determined by immunohistochemistry on tissue samples obtained from each adenoma after surgery.
  • Periodical pituitary magnetic resonance imaging and hormonal evaluation were performed during the follow-up.
  • Pituitary magnetic resonance imaging showed residual/recurrent disease in 25 of 68 patients after 6 months.
  • No correlation was found between Ki-67 index and age, tumor size, GH, or IGF-I plasma levels.
  • We suggest routine Ki-67 evaluation in GH-secreting pituitary adenomas.
  • [MeSH-major] Adenoma / pathology. Growth Hormone-Secreting Pituitary Adenoma / pathology. Ki-67 Antigen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460561.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 51110-01-1 / Somatostatin
  •  go-up   go-down


50. Mantovani G, Lania AG, Spada A: GNAS imprinting and pituitary tumors. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):15-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GNAS imprinting and pituitary tumors.
  • Evidence from in vitro studies and naturally occurring human diseases indicate that several endocrine cells, and particularly somatotrophs, recognize cAMP as a growth factor.
  • Accordingly, mutations of the alpha subunit of the stimulatory G protein gene (GNAS) leading to the constitutive activation of adenylyl cyclase (the so-called gsp oncogene) have been found in a significant proportion of GH-secreting pituitary adenomas.
  • This complex tissue-specific imprinting control results in a near-exclusive expression of Gsalpha from the maternal allele in specific endocrine tissues, including the pituitary.
  • Due to the monoallelic origin of Gsalpha in normal pituitary gsp mutations occur on a maternal allele in order to have a phenotypic effect in both sporadic GH-secreting adenomas and those associated with the McCune-Albright syndrome.
  • Therefore, genetic and epigenetic alterations of the GNAS gene, with subsequent dysregulation of the cAMP pathway, appear, to date, the only molecular hallmark of most GH-secreting adenomas.
  • [MeSH-major] GTP-Binding Protein alpha Subunits, Gs / genetics. Pituitary Neoplasms / genetics
  • [MeSH-minor] Animals. Cyclic AMP-Dependent Protein Kinases / metabolism. Fibrous Dysplasia, Polyostotic / genetics. Genomic Imprinting. Growth Hormone-Secreting Pituitary Adenoma / genetics. Humans. Mice. Pituitary Gland / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20398730.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.6.1.- / GNAS protein, human; EC 3.6.1.- / Gnas protein, mouse; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


51. Donangelo I, Marcos HP, Araújo PB, Marcondes J, Filho PN, Gadelha M, Chimelli L: Expression of retinoblastoma protein in human growth hormone-secreting pituitary adenomas. Endocr Pathol; 2005;16(1):53-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of retinoblastoma protein in human growth hormone-secreting pituitary adenomas.
  • Its role in the pathogenesis of pituitary tumors has not been fully clarified.
  • Conversely, lack of expression of pRB was observed in one fourth of GH-secreting pituitary adenomas (GH-tumors).
  • In order to further study the expression of pRB in GH-tumors, we evaluated this protein in 49 tumors from patients with acromegaly (20 noninvasive, 25 invasive, and 4 with no information) and 8 normal pituitaries using immunohistochemistry (IHC).
  • In conclusion, pRB is underexpressed in a subgroup of GH-tumors, and this may represent an early event in the pathogenesis of this tumor subtype.
  • [MeSH-major] Adenoma / secretion. Human Growth Hormone / secretion. Pituitary Gland, Anterior / secretion. Pituitary Neoplasms / secretion. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Acromegaly / etiology. Acromegaly / metabolism. Acromegaly / pathology. Adult. Aged. Cell Count. Child. Female. Fluorescent Antibody Technique, Indirect. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000847.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoblastoma Protein; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


52. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A: Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol; 2005 Jan;152(1):61-6
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
  • INTRODUCTION: Invasive GH-secreting pituitary adenomas are rarely cured by surgery and although long-term therapy with somatostatin analogs (SSAs) may be employed, hormonal control is achieved in only 60% of cases.
  • The impact of tumor debulking on subsequent control of acromegaly with SSAs has not been studied previously.
  • A case review identified 24 acromegalic patients who had received SSA therapy for > or = 1 month before and after gross total resection or debulking of adenomas.
  • GH and IGV-I responses to SSAs were recorded pre- and postoperatively.
  • RESULTS: Before preoperative SSA treatment, 24/24 (100%) patients had elevated GH levels and IGF-I levels were elevated in 19/21 (90.5%) patients with recorded values.
  • During preoperative SSA treatment, GH and IGF-I levels were normalized in 7/24 (29.2%) and 11/24 (45.8%) patients respectively.
  • Following postoperative washout, GH was controlled in only 3/24 (12.5%) patients, while IGF-I was controlled in 8/19 (42.1%) patients with available data.
  • During the second SSA treatment period, normal GH levels were seen in 13/24 (54.2%) patients, while IGF-I control was noted in 18/23 (78.3%).
  • CONCLUSION: Gross total tumor resection or debulking increases the likelihood of achieving biochemical disease control with SSAs in acromegalic patients with adenomas that were not amenable to complete surgical resection and in whom primary SSA therapy was unable to achieve good biochemical control.

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Endocrinol. 2005 May;152(5):693-4 [15879353.001]
  • (PMID = 15762188.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  • [Number-of-references] 18
  •  go-up   go-down


53. Drutel A, Caron P, Archambeaud F: [New medical treatments in pituitary adenomas]. Ann Endocrinol (Paris); 2008 Sep;69 Suppl 1:S16-28
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New medical treatments in pituitary adenomas].
  • Currently, the role of dopaminergic and somatostatinergic agonists in the treatment of pituitary adenomas is quite well established.
  • Nevertheless, a clearer understanding of the expression of dopaminergic and somatostatinergic receptors at the cellular level of pituitary adenomas as well as the development of newer analogues compounds may drastically change current therapeutic modalities.
  • In the midst of GH-secreting pituitary adenomas, a positive correlation exists between the expression of Sst2 mRNA and the inhibition of GH release by somatostatin analogues.
  • The involvement of Sst5 subtype in adenomas resistant to preferential Sst2 agonists has recently been proved.
  • SOM-230 could therefore allow for much more effective methods in treating patients suffering from acromegaly.
  • Besides, the use of a chimeric molecule presenting a binding affinity to both Sst2 and D2 subtypes (BIM-23A287) inhibits the secretion of GH in ways similar to the Sst2 or D2 agonists used alone or concurrently but however in a concentration 50 times lower than that of the latter.
  • The discovery of Sst5 and D2 subtypes at the level of corticotropic adenomas reveals newer therapeutic perspectives with promising preliminary results with the use of SOM-230 ; these finding lead to a rise in interest in cabergoline.
  • In the midst of non-functioning pituitary adenomas, the expression of Sst2, Sst3 and D2 receptors will perhaps allow the use of combined therapies associating the new somatostatin analogues to the dopaminergic agonists or even use dopastatin (BIM-23A760, chimeric molecule Sst2-Sst5-D2).
  • Nevertheless, it seems that adenomas resistant to dopaminergic agonist due to a lack of expression of D2 receptor fail to express Sst5 receptors as well.
  • On the other hand, dopastatin appears to be more efficient than cabergoline in the management of this type of adenomas.
  • Therefore, the growing awareness concerning the mechanisms involved in the control of pituitary secretions as well as cellular proliferation will perhaps allow physicians to treat the pathology of pituitary adenomas, macroadenomas in particular, using solely pharmacological means instead of invasive surgical procedures and/or radiotherapy.
  • [MeSH-major] Adenoma / drug therapy. Pituitary Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18954854.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Peptides, Cyclic; 0 / Receptors, Dopamine; 0 / Receptors, Somatostatin; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 49
  •  go-up   go-down


54. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM, Pasireotide Acromegaly Study Group: Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab; 2010 Jun;95(6):2781-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
  • Because most GH-secreting pituitary adenomas express sst(2) and sst(5), pasireotide has the potential to be more effective than the sst(2)-preferential somatostatin analogs octreotide and lanreotide.
  • OBJECTIVE: Our objective was to evaluate the efficacy and safety of three different doses of pasireotide in patients with acromegaly.
  • PATIENTS: Sixty patients with acromegaly, defined by a 2-h five-point mean GH level higher than 5 microg/liter, lack of suppression of GH to less than 1 microg/liter after oral glucose tolerance test, and elevated IGF-I for age- and sex-matched controls.
  • MAIN OUTCOME MEASURE: A biochemical response was defined as a reduction in GH to no more than 2.5 microg/liter and normalization of IGF-I to age- and sex-matched controls.
  • After 4 wk of pasireotide 200-600 microg s.c. bid, 19% of patients achieved a biochemical response, which increased to 27% after 3 months of pasireotide; 39% of patients had a more than 20% reduction in pituitary tumor volume.
  • CONCLUSIONS: Pasireotide is a promising treatment for acromegaly.
  • Larger studies of longer duration evaluating the efficacy and safety of pasireotide in patients with acromegaly are ongoing.
  • [MeSH-major] Acromegaly / drug therapy. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Glucose / metabolism. Cross-Over Studies. Dose-Response Relationship, Drug. Double-Blind Method. Endpoint Determination. Female. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Octreotide / adverse effects. Octreotide / therapeutic use. Pituitary Neoplasms / pathology. Young Adult

  • Genetic Alliance. consumer health - Acromegaly.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Endocrinol. 2010 Aug;6(8):417 [20681073.001]
  • (PMID = 20410233.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00088582
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 98H1T17066 / pasireotide; RWM8CCW8GP / Octreotide
  • [Investigator] Brue T; Caron P; Chanson P; Cuneo R; Díaz A; Ghigo E; Gaillard R; Halperin I; Kleinberg D; Rohmer V; Romijn JA; Schlienger JL; Stewart P; Tabarin A; Trainer PJ; van der Lely AJ; Vance ML
  •  go-up   go-down


55. Uccella S, Tibiletti MG, Bernasconi B, Finzi G, Oldrini R, Capella C: Aneuploidy, centrosome alteration and securin overexpression as features of pituitary somatotroph and lactotroph adenomas. Anal Quant Cytol Histol; 2005 Oct;27(5):241-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy, centrosome alteration and securin overexpression as features of pituitary somatotroph and lactotroph adenomas.
  • OBJECTIVE: To verify the presence of numerical chromosomal aberrations (NCAs) in different types of pituitary adenomas (PAs) and to investigate 2 of the mechanisms that are possibly related to aneuploidies in PAs: securin overexpression and centrosome alterations.
  • RESULTS: At interphase FISH analysis, growth hormone (GH)-cell and prolactin (PRL)-cell PAs showed multiple chromosome gains and a low frequency of chromosome losses, suggesting a hyperdiploid chromosome assessment.
  • In addition, when compared to other types of PAs, GH-cell and PRL-cell adenomas showed overexpression of securin and a higher number of both cells with abnormal nuclear shape and cells with centrosomes.
  • CONCLUSION: Somatotroph and lactotroph adenomas are characterized by aneuploidy, abnormal nuclear shape and centrosome amplification, which are possibly related to securin overexpression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447816.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  •  go-up   go-down


56. Fracassi F, Gandini G, Diana A, Preziosi R, Ingh TS, Famigli-Bergamini P, Kooistra HS: Acromegaly due to a somatroph adenoma in a dog. Domest Anim Endocrinol; 2007 Jan;32(1):43-54
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly due to a somatroph adenoma in a dog.
  • The basal serum growth hormone (GH) concentration was markedly elevated (23microg/l) and did not decrease during a glucose tolerance test or after somatostatin administration.
  • The serum insulin-like growth factor-1 concentration was also markedly elevated (1254microg/l).
  • CT scanning of the skull showed an enlarged pituitary gland with normal enhancement pattern.
  • The pituitary gland contained an acidophilic adenoma that immunostained positively for GH (and negatively for ACTH and alpha-MSH).
  • In conclusion, this Dalmatian dog with acromegaly and insulin resistance represents the first case of GH hypersecretion proven to be due to a somatotroph adenoma.
  • [MeSH-major] Acromegaly / veterinary. Adenoma / veterinary. Dog Diseases / pathology. Pituitary Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Fatal Outcome. Growth Hormone / blood. Insulin Resistance. Male. Spinal Osteophytosis / complications. Spinal Osteophytosis / pathology. Spinal Osteophytosis / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472961.001).
  • [ISSN] 0739-7240
  • [Journal-full-title] Domestic animal endocrinology
  • [ISO-abbreviation] Domest. Anim. Endocrinol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


57. Metzler M, Luedecke DK, Saeger W, Grueters A, Haberl H, Kiess W, Repp R, Rascher W, Doetsch J: Low prevalence of Gs alpha mutations in śomatotroph adenomas of children and adolescents. Cancer Genet Cytogenet; 2006 Apr 15;166(2):146-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low prevalence of Gs alpha mutations in śomatotroph adenomas of children and adolescents.
  • Mutations in the gene coding for the alpha-subunit of the heterotrimeric stimulatory G protein Gs are the most frequently identified molecular events in the development of somatotroph adenomas in adults.
  • In children and adolescents, somatotroph adenomas are rare, and only two cases with the Gs alpha mutation have been reported so far.
  • In this study, we therefore investigated the prevalence of activating Gs alpha mutations in 17 patients younger than 20 years with pituitary growth hormone-secreting adenomas and examined the characteristics of mutation-positive cases.
  • Interestingly, in contrast to the remaining cases, the adenomas positive for the Gs alpha mutation proved to be nonsporadic, but part of a syndrome associated with endocrine tumors in both individuals.
  • In contrast to the findings in adult cases, somatotroph adenomas in young patients seem to carry somatic Gs alpha mutations at a lower frequency, and germ-line or early postzygotic mutational events may be responsible for the shortened latency of tumorigenesis.
  • [MeSH-major] GTP-Binding Protein alpha Subunits, Gs / genetics. Growth Hormone-Secreting Pituitary Adenoma / genetics. Mutation / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631471.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


58. Kurosaki M, Saegert W, Abe T, Lüdecke DK: Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res; 2008 Jun;30(5):518-22
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment.
  • OBJECTIVE: The present study was designed to investigate the localization of VEGF in GH-secreting pituitary adenomas and to evaluate the characteristic differences of VEGF expression in relation to the clinical effect of preoperative treatment with octreotide.
  • METHODS: Fifty-six cases of GH-secreting adenomas, which were divided into three groups and three normal pituitary glands, were studied using immunohistochemistry for expression of VEGF.
  • VEGF staining was strongly seen in the cytoplasm in normal pituitary glands.
  • The staining pattern differs statistically between the octreotide and control group, typically in densely granulated GH cell adenomas.
  • Age, gender, tumor size, tumor invasiveness and adenoma type did not influence VEGF expression.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Pituitary Gland / drug effects. Pituitary Gland / metabolism. Pituitary Gland / pathology. Retrospective Studies. Statistics, Nonparametric. Technology, Radiologic / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953743.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Vascular Endothelial Growth Factor A; RWM8CCW8GP / Octreotide
  •  go-up   go-down


59. Yamazaki M, Sato A, Nishio S, Takeda T, Miyamoto T, Katai M, Hashizume K: Acromegaly accompanied by Turner syndrome with 47,XXX/45,X/46,XX mosaicism. Intern Med; 2009;48(6):447-53
MedlinePlus Health Information. consumer health - Turner Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly accompanied by Turner syndrome with 47,XXX/45,X/46,XX mosaicism.
  • A pituitary adenoma with elevated serum levels of growth hormone (GH) and insulin-like growth factor-I (IGF-I) was detected, indicating acromegaly caused by GH-secreting pituitary adenoma.
  • Transsphenoidal resection of the tumor decreased serum GH and IGF-I levels, but the edema was not improved.
  • This case may indicate the important relationships between GH/IGF-I and Turner syndrome.
  • [MeSH-major] Acromegaly / genetics. Chromosomes, Human, X / genetics. Mosaicism. Turner Syndrome / genetics
  • [MeSH-minor] Adenoma / blood. Adenoma / complications. Adenoma / diagnosis. Adult. Diagnosis, Differential. Female. Growth Hormone / blood. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Pituitary Neoplasms / blood. Pituitary Neoplasms / complications. Pituitary Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - 47 XXX Syndrome.
  • Genetic Alliance. consumer health - Turner syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19293545.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


60. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab; 2005 Jul;90(7):4405-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
  • CONTEXT: Somatostatin analogs have been successfully used to treat patients with GH-secreting pituitary adenomas because they are safe, effective, and usually well tolerated.
  • The results of studies evaluating acromegaly treatment with the somatostatin receptor ligands (SRLs), octreotide and lanreotide, have supported the use of these agents for primary medical therapy before or as an alternative to traditional interventions of surgery and radiotherapy in selected cases.
  • EVIDENCE ACQUISITION: We therefore undertook a systematic literature overview to characterize the results of studies involving primary therapy with somatostatin analogs and their effects on pituitary tumor size.
  • Because most studies in which pituitary tumor shrinkage has been assessed involve uncontrolled, open-label, prospective trials or retrospective case series, the lack of a control arm does not permit pooling of data in a metaanalytic fashion to determine tumor size reduction.
  • EVIDENCE SYNTHESIS: Overall, for patients who experience significant shrinkage, an approximately 50% decrease in pituitary mass is achieved when a somatostatin analog is used exclusively or before surgery or radiotherapy.
  • Fourteen studies (n = 424) provided a definition of significant tumor shrinkage, and the results showed that 36.6% (weighted mean percentage) of patients receiving primary SRL therapy for acromegaly experienced a significant reduction in tumor size.
  • [MeSH-major] Acromegaly / drug therapy. Pituitary Neoplasms / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Dopamine Agonists / therapeutic use. Humans. Insulin-Like Growth Factor I / analysis

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827109.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


61. Ronchi CL, Ferrante E, Rizzo E, Giavoli C, Verrua E, Bergamaschi S, Lania AG, Beck-Peccoz P, Spada A: Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients. Clin Endocrinol (Oxf); 2008 Oct;69(4):608-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients.
  • OBJECTIVE: Long-term effects of trans-naso-sphenoidal surgery (TNS) or long-acting somatostatin analogs (SSA) on the function of hypothalamic-pituitary-adrenal (HPA) axis have been poorly investigated.
  • Aim of this study was to evaluate HPA axis integrity during the follow-up in patients with GH-secreting pituitary adenomas and preserved HPA function post-TNS or prior SSA.
  • No significant correlations between HPA axis deterioration and follow-up duration, serum GH/IGF-I levels, occurrence of other pituitary deficiencies, presence of secondary empty sella, changes in tumour or residual volume were observed.
  • [MeSH-major] Acromegaly / physiopathology. Hypothalamo-Hypophyseal System / physiology. Pituitary-Adrenal System / physiology
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / metabolism. Adenoma / physiopathology. Adrenocorticotropic Hormone / blood. Adrenocorticotropic Hormone / metabolism. Adult. Aged. Basal Metabolism / physiology. Delayed-Action Preparations. Disease Progression. Female. Follow-Up Studies. Humans. Hydrocortisone / blood. Hydrocortisone / metabolism. Male. Middle Aged. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / physiopathology. Retrospective Studies. Somatostatin / administration & dosage. Somatostatin / analogs & derivatives. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410544.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 51110-01-1 / Somatostatin; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


62. Nasr C, Mason A, Mayberg M, Staugaitis SM, Asa SL: Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma. J Clin Endocrinol Metab; 2006 Dec;91(12):4776-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma.
  • CONTEXT: GHRH excess from extracranial endocrine tumors is known to cause somatotroph hyperplasia and acromegaly.
  • Hypothalamic gangliocytomas producing GHRH are also known to be associated with pituitary adenomas causing acromegaly.
  • OBJECTIVES: The objective of this study was to describe a case of acromegaly due to a pulmonary GHRH-secreting endocrine carcinoma with metastasis to the pituitary gland and to look at the peculiar histological features of this case.
  • Her disease was clinically stable for 7 yr until she developed bitemporal hemianopia.
  • She had symptoms and signs of acromegaly.
  • Endocrine studies showed elevated serum levels of GH, prolactin, alpha-subunit of glycoprotein hormones, IGF-I, chromogranin A, and GHRH.
  • Postoperatively, she noted an improvement in symptoms of acromegaly.
  • Histological examination confirmed metastatic endocrine carcinoma to the pituitary, and immunohistochemistry localized GHRH to the tumor cells.
  • The adjacent pituitary exhibited somatotroph hyperplasia with abundant reactivity for GH and alpha-subunit.
  • In addition, there was focal neoplastic transformation to a sparsely granulated somatotroph phenotype with fibrous bodies.
  • CONCLUSION: This is the first report of a GHRH-producing endocrine tumor metastasizing to the pituitary and causing local hyperstimulation with somatotroph hyperplasia and adenomatous transformation.
  • [MeSH-major] Acromegaly / complications. Acromegaly / etiology. Adenoma / etiology. Carcinoma / complications. Growth Hormone-Releasing Hormone / secretion. Lung Neoplasms / complications. Paraneoplastic Endocrine Syndromes / complications. Pituitary Neoplasms / secondary. Somatotrophs / pathology

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968791.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones, Ectopic; 0 / Indium Radioisotopes; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


63. Horvath E, Kovacs K: Pathology of acromegaly. Neuroendocrinology; 2006;83(3-4):161-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of acromegaly.
  • This review summarizes current knowledge on pituitary changes in patients with acromegaly.
  • The histologic, immunohistochemical and electron microscopic study provided conclusive evidence that a marked diversity exists between the tumors which secrete growth hormone (GH) in excess, such as densely and sparsely granulated GH cell adenoma, the mixed GH prolactin cell adenoma and the mammosomatotrope adenoma.
  • The latter two tumors produce GH and prolactin simultaneously.
  • Densely granulated GH cell tumors may produce thyrotropin and alpha subunit as well.
  • Somatotrope carcinomas are extremely rare.
  • GH cell hyperplasia can also be associated with acromegaly in patients with extrapituitary GH-releasing hormone secreting tumors.
  • The medical therapy of acromegaly is reviewed briefly, including long-acting somatostatin analogs and pegvisomant, a GH receptor blocker.
  • [MeSH-major] Acromegaly / pathology. Human Growth Hormone / metabolism. Pituitary Gland / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenoma / therapy. Adenoma / ultrastructure. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma / therapy. Carcinoma / ultrastructure. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047379.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  • [Number-of-references] 22
  •  go-up   go-down


64. Fougner SL, Bollerslev J, Latif F, Hald JK, Lund T, Ramm-Pettersen J, Berg JP: Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Metab; 2008 Apr;93(4):1211-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment.
  • CONTEXT: Excessive GH production by pituitary tumors causes acromegaly.
  • Medical treatment of acromegaly with somatostatin analogs (SMSs), like octreotide, is well established, but the clinical effect is variable.
  • OBJECTIVE: Our objective was to study RKIP levels in pituitary somatotroph adenomas, and relate them to clinical characteristics and response to octreotide treatment in patients with acromegaly.
  • PATIENTS AND METHODS: RKIP level was analyzed by Western blot of proteins extracted from somatotroph tumors frozen a short time after surgery in 51 patients with active acromegaly.
  • RESULTS: The adenoma RKIP level correlated significantly to both the acute and the long-term octreotide responses on serum levels of GH and IGF-I, respectively.
  • In multiple regression analyses, the RKIP level was a significant determinant for both the GH reduction in the acute test and the IGF-I reduction after approximately 6 months.
  • CONCLUSION: The RKIP level in somatotroph adenomas seems to be important for the clinical effect of SMS treatment, in which low levels of RKIP correlate to poor clinical response to SMSs.
  • [MeSH-major] Adenoma / chemistry. Antineoplastic Agents, Hormonal / therapeutic use. Growth Hormone-Secreting Pituitary Adenoma / chemistry. Octreotide / therapeutic use. Phosphatidylethanolamine Binding Protein / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18230656.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / PEBP1 protein, human; 0 / Phosphatidylethanolamine Binding Protein; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; RWM8CCW8GP / Octreotide
  •  go-up   go-down


65. Daems T, Verhelst J, Michotte A, Abrams P, De Ridder D, Abs R: Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary; 2009;12(1):80-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modification of hormonal secretion in clinically silent pituitary adenomas.
  • BACKGROUND: Silent pituitary adenomas are a subtype of adenomas characterized by positive immunoreactivity for one or more hormones classically secreted by normal pituitary cells but without clinical expression, although in some occasions enhanced or changed secretory activity can develop over time.
  • Silent corticotroph adenomas are the classical example of this phenomenon.
  • PATIENTS AND METHODS: A series of about 500 pituitary adenomas seen over a period of 20 years were screened for modification in hormonal secretion.
  • RESULTS: Two cases were retrieved, one silent somatotroph adenoma and one thyrotroph adenoma, both without specific clinical features or biochemical abnormalities, which presented 20 years after initial surgery with evidence of acromegaly and hyperthyroidism, respectively.
  • While the acromegaly was controlled by a combination of somatostatin analogs and growth hormone (GH) receptor antagonist therapy, neurosurgery was necessary to manage the thyrotroph adenoma.
  • Immunohistochemical examination demonstrated an increase in the number of thyroid stimulating hormone (TSH)-immunoreactive cells compared to the first tissue.
  • Apparently, the mechanisms responsible for the secretory modifications are different, being a change in secretory capacity in the silent somatotroph adenoma and a quantitative change in the silent thyrotroph adenoma.
  • CONCLUSIONS: These two cases, one somatotroph and one thyrotroph adenoma, are an illustration that clinically silent pituitary adenomas may in rare circumstances evolve over time and become active, as previously demonstrated in silent corticotroph adenomas.
  • [MeSH-major] Pituitary Neoplasms / metabolism
  • [MeSH-minor] Acromegaly / drug therapy. Acromegaly / metabolism. Acromegaly / surgery. Adult. Human Growth Hormone / secretion. Humans. Immunohistochemistry. Insulin-Like Growth Factor I / secretion. Male. Thyrotropin / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18350381.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9002-71-5 / Thyrotropin
  • [Number-of-references] 30
  •  go-up   go-down


66. Melmed S: Acromegaly pathogenesis and treatment. J Clin Invest; 2009 Nov;119(11):3189-202
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly pathogenesis and treatment.
  • Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting pituitary adenoma and leads to acromegaly - a disorder of disproportionate skeletal, tissue, and organ growth.
  • High GH and IGF1 levels lead to comorbidities including arthritis, facial changes, prognathism, and glucose intolerance.
  • This Review discusses acromegaly pathogenesis and management options.
  • Somatostatin receptor (SSTR) ligands inhibit GH release, control tumor growth, and attenuate peripheral GH action, while GH receptor antagonists block GH action and effectively lower IGF1 levels.
  • Effective control of GH and IGF1 hypersecretion and ablation or stabilization of the pituitary tumor mass lead to improved comorbidities and lowering of mortality rates for this hormonal disorder.

  • Genetic Alliance. consumer health - Acromegaly.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1255-63 [19158203.001]
  • [Cites] Annu Rev Pathol. 2009;4:97-126 [19400692.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1500-8 [19208728.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1509-17 [19208732.001]
  • [Cites] J Biol Chem. 2009 Jul 24;284(30):19937-44 [19460757.001]
  • [Cites] Science. 2000 Apr 7;288(5463):154-7 [10753124.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1171-7 [10770982.001]
  • [Cites] Recent Prog Horm Res. 2000;55:237-66; discussion 266-7 [11036940.001]
  • [Cites] Dev Biol. 2001 Jan 1;229(1):141-62 [11133160.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1716-23 [11297608.001]
  • [Cites] Neurosurgery. 2001 Jun;48(6):1239-43; discussion 1244-5 [11383725.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4072-7 [11549628.001]
  • [Cites] Endocr Rev. 2001 Dec;22(6):800-17 [11739334.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1262-7 [11889197.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8 [12107192.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4142-6 [12213862.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):306-11 [12355087.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63 [12364434.001]
  • [Cites] Endocrinology. 2003 Mar;144(3):967-74 [12586774.001]
  • [Cites] Horm Res. 2003;60(2):53-60 [12876414.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4239-45 [12970293.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1139-47 [13679528.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5414-21 [14602782.001]
  • [Cites] Nat Rev Drug Discov. 2003 Dec;2(12):999-1017 [14654798.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):638-45 [14764775.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1613-7 [15070920.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):720-4 [15208626.001]
  • [Cites] J Clin Invest. 2004 Aug;114(3):349-56 [15286801.001]
  • [Cites] N Engl J Med. 1979 Nov 22;301(21):1138-42 [492275.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1239-45 [16403824.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403 [16449332.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):459-71 [16766265.001]
  • [Cites] Clin Chim Acta. 2006 Nov;373(1-2):176-9 [16815351.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15558-63 [17030811.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):24-9 [17133108.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2558-73 [17167139.001]
  • [Cites] Eur J Endocrinol. 2007 Jan;156(1):75-82 [17218728.001]
  • [Cites] Mol Cell Biol. 2007 Feb;27(4):1495-504 [17145768.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):302-10 [17315038.001]
  • [Cites] Rev Endocr Metab Disord. 2006 Dec;7(4):225-35 [17308965.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4101-5 [17360484.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Pituitary. 2007;10(2):165-72 [17458702.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68 [17465997.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Jul;67(1):65-70 [17437512.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Aug;67(2):282-9 [17524029.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Aug;67(2):310-5 [17555503.001]
  • [Cites] Eur J Endocrinol. 2007 Oct;157(4):371-82 [17893250.001]
  • [Cites] IDrugs. 2007 Dec;10(12):885-95 [18041687.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jan;93(1):61-7 [17971431.001]
  • [Cites] Rev Endocr Metab Disord. 2008 Mar;9(1):33-9 [18075787.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):1984-96 [18381936.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1412-7 [18211974.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Recent Prog Horm Res. 1999;54:397-438; discussion 438-9 [10548885.001]
  • [Cites] Nature. 1999 Dec 9;402(6762):656-60 [10604470.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):707-14 [10690880.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] Endocrinology. 1983 Apr;112(4):1553-5 [6131812.001]
  • [Cites] Endocr Rev. 1983 Spring;4(2):97-130 [6345149.001]
  • [Cites] Endocrinology. 1984 Nov;115(5):1952-7 [6149116.001]
  • [Cites] Nature. 1987 Dec 10-16;330(6148):566-8 [2825031.001]
  • [Cites] J Clin Invest. 1988 Apr;81(4):968-75 [3127426.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5061-5 [2367524.001]
  • [Cites] Endocrinology. 1990 Sep;127(3):1033-40 [2387246.001]
  • [Cites] Ann Intern Med. 1990 Dec 15;113(12):921-5 [2240917.001]
  • [Cites] Endocrinology. 1990 Dec;127(6):3187-95 [2123448.001]
  • [Cites] N Engl J Med. 1991 Dec 12;325(24):1688-95 [1944469.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Apr;74(4):914-9 [1312542.001]
  • [Cites] Mol Endocrinol. 1992 Apr;6(4):598-606 [1584223.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):597-614 [1521514.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9826-30 [1409707.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):724-9 [7521350.001]
  • [Cites] Mol Endocrinol. 1995 Jul;9(7):777-83 [7476961.001]
  • [Cites] Recent Prog Horm Res. 1996;51:189-215; discussion 215-6 [8701079.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):789-98 [9045884.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7239-44 [9207075.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11381-6 [9326618.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] Nat Genet. 1998 Apr;18(4):360-4 [9537419.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3808-16 [9814451.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1518-23 [10323372.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 May;50(5):561-7 [10468920.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51100-6 [15456744.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1772-9 [15618350.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Curr Opin Genet Dev. 2005 Jun;15(3):332-40 [15917210.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):24011-21 [15857828.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10 [15827109.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4483-8 [15899958.001]
  • [Cites] Nat Struct Mol Biol. 2005 Sep;12(9):814-21 [16116438.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Jun;68(6):970-5 [18031313.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2390-401 [18381572.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2035-41 [18381584.001]
  • [Cites] Cell. 2008 Jun 13;133(6):1019-31 [18555778.001]
  • [Cites] Endocrinology. 2008 Jul;149(7):3294-305 [18388193.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(10):1984-9 [17888716.001]
  • [Cites] Clin Chem. 2008 Aug;54(8):1268-76 [18567697.001]
  • [Cites] Eur J Endocrinol. 2008 Aug;159(2):89-95 [18524797.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Aug;93(8):2957-68 [18477663.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Aug;93(8):2984-90 [18492760.001]
  • [Cites] Mol Endocrinol. 2008 Sep;22(9):2190-202 [18635665.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3411-5 [18611972.001]
  • [Cites] Mol Endocrinol. 2008 Oct;22(10):2278-92 [18653781.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4119-25 [18628527.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10163-70 [19074883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20452-7 [19088192.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):218-22 [18957501.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):523-7 [19033371.001]
  • [Cites] Mol Endocrinol. 2009 Mar;23(3):337-48 [19131507.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1844-50 [19223528.001]
  • [Cites] Eur J Endocrinol. 2009 Apr;160(4):543-8 [19141605.001]
  • [Cites] Clin Endocrinol (Oxf). 2009 May;70(5):757-68 [19178516.001]
  • (PMID = 19884662.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA 075979
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  • [Number-of-references] 125
  • [Other-IDs] NLM/ PMC2769196
  •  go-up   go-down


67. Roberts BK, Ouyang DL, Lad SP, Chang SD, Harsh GR 4th, Adler JR Jr, Soltys SG, Gibbs IC, Remedios L, Katznelson L: Efficacy and safety of CyberKnife radiosurgery for acromegaly. Pituitary; 2007;10(1):19-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of CyberKnife radiosurgery for acromegaly.
  • OBJECTIVE: Acromegaly is a disease characterized by GH hypersecretion, and is typically caused by a pituitary somatotroph adenoma.
  • The primary mode of therapy is surgery, and radiotherapy is utilized as an adjuvant strategy to treat persistent disease.
  • The aim of this study was to determine the efficacy and tolerability of CyberKnife stereotactic radiosurgery in acromegaly.
  • DESIGN: A retrospective review of biochemical and imaging data for subjects with acromegaly treated with CyberKnife stereotactic radiosurgery between 1998 and 2005 at Stanford University Hospital.
  • PATIENTS: Nine patients with active acromegaly were treated with radiosurgery using the CyberKnife (CK).
  • MEASUREMENTS: Biochemical response based on serum insulin-like growth factor-1 (IGF-1), anterior pituitary hormone function, and tumor size with MRI scans were analyzed.
  • Smaller tumor size was predictive of treatment success: baseline tumor volume was 1.28 cc (+/- 0.81, SD) vs. 3.93 cc (+/- 1.54) in subjects with a normal IGF-1 vs. those with persistent, active disease, respectively (P = 0.02).
  • The mean biologically effective dose (BED) was higher in subjects who achieved a normal IGF-1 vs. those with persistent, active disease, 172 Gy(3) (+/-28) vs. 94 Gy(3) (+/-17), respectively (P < 0.01).
  • At least one new anterior pituitary hormone deficiency was observed after CK in 3 (33%) patients: two developed hypogonadism, and one developed panhypopituitarism.
  • CONCLUSIONS: CK radiosurgery may be a valuable adjuvant therapy for the management of acromegaly.
  • [MeSH-major] Acromegaly / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Radiosurgery
  • [MeSH-minor] Adult. Female. Humans. Insulin-Like Growth Factor I / analysis. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Acromegaly.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pituitary. 2007;10(1):17. Remedios, Lynn [added]
  • [ErratumIn] Pituitary. 2007 Mar;10(1):17 [27519534.001]
  • (PMID = 17273921.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


68. Matsuno A: [Recent trends in the pathophysiology and treatment of pituitary adenomas]. Brain Nerve; 2009 Aug;61(8):957-62
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent trends in the pathophysiology and treatment of pituitary adenomas].
  • Recent molecular pathological investigations have elucidated the cytodifferentiation of pituitary cells and identified several transcriptional factors that regulate this cytodifferentiation of pituitary cells.
  • The patterns of cytodifferentiation are closely related to the pathogenesis of pituitary adenomas.
  • Meanwhile, the role of hypothalamic hormones in the development of pituitary adenomas has recently attracted the attention of investigators.
  • The expression of growth hormone-releasing hormone and corticotrophin releasing hormone in corticotroph adenomas have been demonstrated in somatotroph adenomas and corticotropin adenomas, respectively.
  • This finding indicates that the endogenous expression of hypothalamic hormones and their receptors in human pituitary adenoma cells has ample significance in the autocrine or paracrine regulation of pituitary hormone production and tumor extension induced by hypothalamic hormones produced by adenoma cells.
  • The recent progress in surgical techniques for treatment of pituitary adenomas has provided several alternatives: transsphenoidal surgery vs. transcranial surgery, sublabial approach vs. endonasal approach, and microsurgery vs. endoscopic surgery.
  • There have also been developments in the medical treatment of pituitary adenomas.
  • The frequently used dopamine agonist, cabergoline, is very effective for treating prolactin-producing adenoma.
  • Long-acting octreotide and pegvisomant are now available for the treatment of growth hormone producing adenoma.
  • Cabergoline is also used for growth hormone producing adenoma.
  • Temozolomide has recently been used for atypical adenomas or pituitary carcinomas.
  • Adult growth hormone deficiency sometimes occurs in postoperative patients with pituitary adenomas.
  • Growth hormone replacement is recommended to maintain the quality of life of these patients.
  • [MeSH-major] Adenoma / etiology. Adenoma / therapy. Pituitary Neoplasms / etiology. Pituitary Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Corticotropin-Releasing Hormone. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Ergolines / therapeutic use. Growth Hormone-Releasing Hormone. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / therapeutic use. Humans. Hypothalamic Hormones. Incidental Findings. Neurosurgical Procedures / methods. Neurosurgical Procedures / trends. Octreotide / therapeutic use. Prolactinoma. Receptors, Neuropeptide. Receptors, Pituitary Hormone-Regulating Hormone

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697885.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; 0 / Hypothalamic Hormones; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / pegvisomant; 0 / somatotropin releasing hormone receptor; 12629-01-5 / Human Growth Hormone; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9015-71-8 / Corticotropin-Releasing Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide
  • [Number-of-references] 32
  •  go-up   go-down


69. Korbonits M, Carlsen E: Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res; 2009 Apr;71 Suppl 2:123-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent clinical and pathophysiological advances in non-functioning pituitary adenomas.
  • Pituitary adenomas are being recognized and diagnosed with increasing frequency.
  • One of the most common forms of pituitary lesion is the clinically non-functioning pituitary adenoma (NFPA), which is often diagnosed incidentally.
  • The vast majority of pituitary adenomas are sporadic, but familial adenomas can occur in the multiple pituitary adenoma type 1 syndrome, in Carney complex or in familial isolated pituitary adenoma.
  • NFPA often show hormone synthesis on tissue immunostaining without causing clinical symptoms.
  • Most often these are silent gonadotroph adenomas, with silent corticotroph or somatotroph adenomas occurring less frequently.
  • It is unclear why these silent adenomas do not release hormones at a clinically recognizable level, although it is probable that there is a continuum between fully functional and completely silent adenomas.
  • Temozolomide has been successfully used for the treatment of a few aggressive pituitary adenomas, and the response to this drug could be influenced by the expression of the DNA repair enzyme O-6-methylguanine DNA methyltransferase.
  • The early diagnosis, prediction of long-term outcome and treatment of NFPAs remain a challenge for endocrinologists.
  • [MeSH-major] Growth Hormone-Secreting Pituitary Adenoma. Prolactinoma
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / diagnosis. ACTH-Secreting Pituitary Adenoma / metabolism. ACTH-Secreting Pituitary Adenoma / pathology. ACTH-Secreting Pituitary Adenoma / therapy. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19407508.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 58
  •  go-up   go-down


70. Saveanu A, Jaquet P, Brue T, Barlier A: Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol Cell Endocrinol; 2008 May 14;286(1-2):206-13
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
  • Dopamine and somatostatin are both involved in the negative control of normal pituitary cells.
  • Dopamine subtype 2 receptor (D2DR) and somatostatin receptor (sst) agonists, mainly directed to sst2, are used in the treatment of pituitary adenomas.
  • Nevertheless, a majority of corticotroph and gonadotroph adenomas and a third of somatotroph adenomas are still not sufficiently controlled by these treatments.
  • D2DR and sst1, 2, 3 and 5 are present in most pituitary adenomas.
  • D2DR and sst2 agonist cotreatment showed limited additivity on GH secretion in acromegaly.
  • Moreover, new chimeric compounds with sst2, D2DR and sst5 affinity have shown an increased control of secretion and/or proliferation of different types of pituitary adenomas in cell culture.
  • Together with the multi-sst ligand drugs recently developed, these dopamine-somatostatin ligands represent a new opportunity in the combinatory treatment of pituitary adenomas.
  • [MeSH-major] Adenoma / drug therapy. Pituitary Neoplasms / drug therapy. Receptors, Dopamine D2 / metabolism. Receptors, Somatostatin / metabolism. Somatostatin / metabolism
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Cell Proliferation / drug effects. Dopamine / analogs & derivatives. Dopamine / therapeutic use. Ergolines / therapeutic use. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Growth Hormone-Secreting Pituitary Adenoma / metabolism. Human Growth Hormone / metabolism. Humans. Octreotide / therapeutic use. Protein Multimerization. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241980.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Ergolines; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide; VTD58H1Z2X / Dopamine
  • [Number-of-references] 90
  •  go-up   go-down


71. Bondanelli M, Bonadonna S, Ambrosio MR, Doga M, Gola M, Onofri A, Zatelli MC, Giustina A, degli Uberti EC: Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Metabolism; 2005 Sep;54(9):1174-80
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
  • Chronic growth hormone (GH)/insulin-like growth factor I (IGF-I) excess is associated with considerable mortality in acromegaly, but no data are available in pituitary gigantism.
  • The aim of the study was to evaluate the long-term effects of early exposure to GH and IGF-I excess on cardiovascular and metabolic parameters in adult patients with pituitary gigantism.
  • Six adult male patients with newly diagnosed gigantism due to GH secreting pituitary adenoma were studied and compared with 6 age- and sex-matched patients with acromegaly and 10 healthy subjects.
  • Disease duration was significantly longer (P<.05) in patients with gigantism than in patients with acromegaly, whereas GH and IGF-I concentrations were comparable.
  • Left ventricular mass was increased both in patients with gigantism and in patients with acromegaly, as compared with controls.
  • Left ventricular hypertrophy was detected in 2 of 6 of both patients with gigantism and patients with acromegaly, and isolated intraventricular septum thickening in 1 patient with gigantism.
  • Inadequate diastolic filling (ratio between early and late transmitral flow velocity<1) was detected in 2 of 6 patients with gigantism and 1 of 6 patients with acromegaly.
  • Impaired glucose metabolism occurrence was higher in patients with acromegaly (66%) compared with patients with gigantism (16%).
  • In conclusion, our data suggest that GH/IGF-I excess in young adult patients is associated with morphologic and functional cardiac abnormalities that are similar in patients with gigantism and in patients with acromegaly, whereas occurrence of impaired glucose metabolism appears to be higher in patients with acromegaly, although patients with gigantism are exposed to GH excess for a longer period.
  • [MeSH-major] Gigantism / complications. Gigantism / metabolism. Human Growth Hormone / blood. Hypertrophy, Left Ventricular / etiology. Hypertrophy, Left Ventricular / metabolism. Insulin-Like Growth Factor I / metabolism
  • [MeSH-minor] Acromegaly / complications. Acromegaly / metabolism. Adult. Blood Pressure. Echocardiography, Doppler. Electrocardiography. Glucose / metabolism. Glucose Intolerance / etiology. Glucose Intolerance / metabolism. Humans. Male. Ventricular Dysfunction, Left / etiology. Ventricular Dysfunction, Left / metabolism. Ventricular Dysfunction, Left / ultrasonography

  • Genetic Alliance. consumer health - Gigantism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125529.001).
  • [ISSN] 0026-0495
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; IY9XDZ35W2 / Glucose
  •  go-up   go-down


72. Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S: Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab; 2008 Apr;93(4):1203-10
Guide to Pharmacology. gene/protein/disease-specific - sst2 receptor - data and references .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas.
  • Although sst2A and sst5 mRNAs are consistently expressed in GH-secreting adenomas, octreotide controls GH secretion only in 65% of acromegalic patients.
  • Hence, we investigated the immunocytochemical expression of sst in a large group of somatotroph tumors.
  • In group B octreotide reduced GH secretion by more than 50% in 14 patients (70%) (GH responders).
  • Six patients with less than 50% GH suppression were considered GH nonresponders.
  • We used a panel of extensively characterized antibodies to determine the immunocytochemical sst status in somatotroph adenomas and compared their expression between the groups.
  • A similar pattern was found in the GH responders of group B.
  • In contrast, none of the GH nonresponders exhibited detectable sst2A (sst2A: GH responders vs. GH nonresponders, P < 0.0001), whereas sst5 was found in 70%.
  • CONCLUSIONS: Our findings suggest that octreotide resistance in GH-secreting adenomas occurs due to a selective loss of sst2A.
  • [MeSH-major] Adenoma / chemistry. Antineoplastic Agents, Hormonal / therapeutic use. Growth Hormone-Secreting Pituitary Adenoma / chemistry. Octreotide / therapeutic use. Receptors, Somatostatin / analysis
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Female. Human Growth Hormone / blood. Humans. Immunohistochemistry. Male. Middle Aged. Molecular Sequence Data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18198230.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


73. Nakashima M, Takano K, Matsuno A: Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas. Endocr J; 2009;56(2):295-304
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas.
  • Somatostatin analogues such as octreotide are used to treat active acromegalic patients by reducing serum growth hormone (GH) levels.
  • However, the acute effect of octreotide on GH secretion differs among patients.
  • To elucidate factors influencing the acute effect of octreotide, we collected data from 56 patients with somatotroph adenoma from two institutions.
  • Monovariate analysis revealed a statistically significant inverse relation of Ki-67 SI with the reduction of GH by octreotide.
  • Post-test revealed that the plasma membrane-dominant staining pattern of SSTR 2A was significantly related to the reduction of GH by octreotide.
  • [MeSH-major] Growth Hormone-Secreting Pituitary Adenoma / secretion. Human Growth Hormone / secretion. Octreotide / therapeutic use. Pituitary Neoplasms / secretion
  • [MeSH-minor] Adult. Aged. Cell Membrane / metabolism. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Receptors, Somatostatin / metabolism. Regression Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164866.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


74. Rotondo F, Scheithauer BW, Kovacs K, Bell DC: Rab3B immunoexpression in human pituitary adenomas. Appl Immunohistochem Mol Morphol; 2009 May;17(3):185-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rab3B immunoexpression in human pituitary adenomas.
  • To shed light on its presence in the normal human pituitary and in adenomas, a detailed immunohistochemical study of 130 surgically removed human pituitary adenomas was undertaken, including 23 somatotroph, 32 lactotroph, 19 functional corticotroph, 10 silent subtype 1 and 8 silent subtype 2 corticotroph adenomas, 12 gonadotroph hormone producing, 10 thyrotroph, 7 silent subtype 3 adenomas, and 9 null cell adenomas, 5 of the latter being of oncocytic type.
  • Among the 32 prolactin lactotroph adenomas, 10 had been treated preoperatively with bromocriptine, a dopamine agonist.
  • Among the 23 somatotroph adenomas, 10 were pretreated with octreotide, a long acting somatostatin analog.
  • The results showed Rab3B immunopositivity to be strongest in corticotroph adenomas followed by thyrotroph, lactotroph, gonadotroph, null cell, and somatotroph adenomas.
  • No difference was noted between endocrinologically active and silent corticotroph adenomas.
  • Our results add new information to the view that Rab3B is involved in the regulation of pituitary hormone secretion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384079.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3A64E3G5ZO / Bromocriptine; EC 3.6.1.- / RAB3B protein, human; EC 3.6.5.2 / rab3 GTP-Binding Proteins; RWM8CCW8GP / Octreotide
  •  go-up   go-down


75. Beuschlein F, Hancke K, Petrick M, Göbel H, Honegger J, Reincke M: Growth hormone receptor mRNA expression in non-functioning and somatotroph pituitary adenomas: implications for growth hormone substitution therapy? Exp Clin Endocrinol Diabetes; 2005 Apr;113(4):214-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone receptor mRNA expression in non-functioning and somatotroph pituitary adenomas: implications for growth hormone substitution therapy?
  • The use of growth hormone (GH) in patients with GH deficiency induced by pituitary adenoma is widely accepted, but the safety of this mitogenic hormone, particularly in patients with residual tumor after neurosurgery, continues to be a concern.
  • Since the mitogenic potency of GH is dependent upon the presence of the GH receptor (GH-R) and the subsequent IGF-1/IGF receptor (IGF-1-R) system we investigated the expression of the members of the growth hormone cascade in endocrine inactive and GH-producing pituitary adenomas.
  • Tissue specimens of 18 clinically non-functioning pituitary adenomas and 6 GH-producing adenomas were collected following transsphenoidal surgery while normal cadaver pituitary glands served as controls.
  • After RNA extraction, semi-quantitative RT-PCR amplification with specific primers for GH, GH-R, IGF-1 and IGF-1-R was performed.
  • Applying this sensitive RT-PCR based approach, GH-R expression was demonstrated in all normal pituitaries, most inactive adenomas (94%), and the majority of GH-producing adenomas (66%).
  • Both IGF-1 and IGF-1-R mRNA was detectable in the majority of inactive (72% and 77%, respectively) and somatotrophic adenomas (83% and 83%).
  • While IGF-1-R mRNA was expressed in all normal pituitary specimen studied, IGF-1 was detectable in only 55% of them.
  • In summary, expression of members of the GH-IGF-1 cascade could be demonstrated in a substantial subset of patients with non-functioning and GH-producing pituitary adenomas.
  • These factors might serve as a substrate for the transduction of mitogenic effects of GH on remnant pituitary tumors during GH replacement therapy.
  • Therefore, GH therapy should be carefully considered and patients on GH therapy kept under close observation.
  • [MeSH-major] Adenoma / genetics. Growth Hormone / analogs & derivatives. Growth Hormone / therapeutic use. Pituitary Neoplasms / genetics. RNA, Messenger / genetics. Receptors, Somatotropin / genetics
  • [MeSH-minor] Acromegaly / genetics. DNA Primers. Gene Expression Regulation, Neoplastic. Humans. Insulin-Like Growth Factor I / genetics. Receptor, IGF Type 1 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891957.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Receptors, Somatotropin; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


76. Mohammed S, Cusimano MD, Scheithauer BW, Rotondo F, Horvath E, Kovacs K: O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report. Neurosurgery; 2010 Feb;66(2):E421-2; discussion E422
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report.
  • OBJECTIVE: Double pituitary adenomas in surgical cases are rarely reported.
  • We present a treatment dilemma of a double adenoma that had differential O-methylguanine-DNA methyltransferase (MGMT) reactivity.
  • CLINICAL PRESENTATION: A 48-year-old man presented with acromegaly and a recurrent pituitary adenoma.
  • He had elevated growth hormone (GH) and elevated insulin-like growth factor blood levels and hyperprolactinemia.
  • Morphologic examination disclosed 2 histologically distinct tumors, including a GH adenoma and a prolactin adenoma.
  • Of significant note was MGMT immunopositivity in the GH adenoma and lack of staining in the prolactin adenoma.
  • CONCLUSION: This is the first clinical instance in which MGMT was assessed in double adenomas of the pituitary.
  • The adenomas underwent recurrence, a feature that reflects their invasive nature and the possibility that chemotherapeutic intervention may be required in the future.
  • Response to temozolomide use is anticipated with respect to the prolactin adenoma but would likely not benefit the GH cell adenoma of our patient.
  • [MeSH-major] Adenoma / enzymology. DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Pituitary Neoplasms / enzymology. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Growth Hormone / blood. Humans. Hyperprolactinemia / etiology. Insulin-Like Growth Factor Binding Proteins / blood. Ki-67 Antigen / metabolism. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087113.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Proteins; 9002-72-6 / Growth Hormone; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


77. Adamo MA, Drazin D, Popp AJ: Short-lasting, unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome treated successfully with transsphenoidal resection of a growth hormone-secreting pituitary adenoma. J Neurosurg; 2008 Jul;109(1):123-5
Genetic Alliance. consumer health - Pituitary adenoma, growth hormone-secreting.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-lasting, unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome treated successfully with transsphenoidal resection of a growth hormone-secreting pituitary adenoma.
  • In this paper the authors present a patient with a growth hormone-secreting pituitary adenoma who experienced resolution of SUNCT syndrome after transsphenoidal tumor resection.
  • [MeSH-major] Adenoma / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. SUNCT Syndrome / surgery

  • Genetic Alliance. consumer health - SHORT syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18590441.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Meij BP, Auriemma E, Grinwis G, Buijtels JJ, Kooistra HS: Successful treatment of acromegaly in a diabetic cat with transsphenoidal hypophysectomy. J Feline Med Surg; 2010 May;12(5):406-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of acromegaly in a diabetic cat with transsphenoidal hypophysectomy.
  • Plasma concentrations of growth hormone (GH) (51 microg/l, reference range 0.8-7.2 microg/l) and insulin-like growth factor 1 (IGF-1) (3871 microg/l, reference range 39-590 microg/l) were highly elevated, whereas those of alpha-melanocyte-stimulating hormone, adrenocorticotropic hormone and cortisol were normal.
  • Computed tomography revealed a thick palatum molle and an enlarged pituitary gland, indicating a pituitary neoplasm.
  • Microsurgical transsphenoidal hypophysectomy was performed and microscopic examination of the surgical specimen revealed an acidophilic, infiltrative pituitary adenoma that showed positive immunostaining for GH.
  • One year after hypophysectomy the plasma concentrations of GH and IGF-1 were 2.4 microg/l and 113 microg/l, respectively.
  • PRACTICAL RELEVANCE: This is the first report detailing transsphenoidal hypophysectomy as a feasible and effective treatment for feline acromegaly due to a pituitary somatotroph adenoma.
  • The surgery is discussed in the context of human and other feline therapies for acromegaly.
  • [MeSH-major] Acromegaly / veterinary. Adenocarcinoma / veterinary. Cat Diseases / surgery. Hypophysectomy / veterinary
  • [MeSH-minor] Adrenocortical Hyperfunction / blood. Adrenocortical Hyperfunction / complications. Adrenocortical Hyperfunction / surgery. Adrenocortical Hyperfunction / veterinary. Animals. Blood Glucose / metabolism. Cats. Diabetes Mellitus / blood. Diabetes Mellitus / surgery. Diabetes Mellitus / veterinary. Growth Hormone / blood. Insulin-Like Growth Factor I / metabolism. Male. Sphenoid Bone. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20417901.001).
  • [ISSN] 1532-2750
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


79. Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM: Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin Endocrinol (Oxf); 2005 Apr;62(4):410-7
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
  • OBJECTIVE: Correction of GH and IGF-I levels are associated with improvements in insulin secretion, cardiac performance and body composition in patients with acromegaly, but whether these parallel post-treatment levels of GH-IGF-I axis activity is undefined.
  • We investigate whether various biochemical outcomes after transsphenoidal pituitary surgery (TSS) in these patients are associated with clinically relevant differences in cardiac performance, insulin resistance and body composition.
  • DESIGN: Cross-sectional study of consecutive patients with acromegaly admitted to the hospital between 2001 and 2002.
  • PATIENTS AND METHODS: Forty-one patients after TSS for somatotroph pituitary adenoma and 23 patients with naive acromegaly serving as positive controls were enrolled in the study.
  • Mean daily GH levels (mGH), IGF-I, leptin and lipid levels, glucose, insulin and GH concentrations during oral glucose tolerance test (oGTT) were measured in all study participants.
  • RESULTS: We found no difference in cardiac indices, insulin resistance, body composition and leptin levels between patients with complete biochemical remission and those with inadequately controlled disease (P > 0.05 for all) after TSS.
  • A similar decrease in LVM(i) was observed in controlled (108.4 +/- 30.0 g/m(2); P = 0.015) and inadequately controlled disease (108.8 +/- 30.7 g/m(2); P = 0.03) in comparison with naive disease (160.3 +/- 80.6 g/m(2)).
  • In controlled and inadequately controlled disease, R(HOMA) index was lower (2.2 +/- 1.4; P = 0.001 and 3.1 +/- 2.0; P = 0.05 vs. 5.1 +/- 3.1) while leptin concentration was higher (14.9 +/- 8.7 microg/l, P = 0.004 and 12.8 +/- 7.8 microg/l, P = 0.05 vs. 7.4 +/- 3.8 microg/l) than in naive disease.
  • Similar results were obtained if the definition of cure included both normal IGF-I levels and the ability to achieve GH nadir < 1 microg/l during oGTT.
  • CONCLUSION: This study shows that cardiac indices, insulin resistance and body composition were not different between patients with complete biochemical remission and those with discordant GH and IGF-I levels.
  • It appears that even incomplete disease control after TSS can result in improvement of these clinical markers.
  • [MeSH-major] Acromegaly / surgery
  • [MeSH-minor] Absorptiometry, Photon. Adenoma / blood. Adenoma / complications. Adenoma / surgery. Adult. Aged. Area Under Curve. Biomarkers / blood. Blood Glucose / analysis. Body Composition. Echocardiography. Female. Growth Hormone / blood. Humans. Insulin / blood. Insulin-Like Growth Factor I / analysis. Leptin / blood. Lipids / blood. Logistic Models. Male. Middle Aged. Pituitary Neoplasms / blood. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. Remission Induction. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807870.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Glucose; 0 / Insulin; 0 / Leptin; 0 / Lipids; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


80. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ: Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab; 2008 Apr;93(4):1412-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy.
  • OBJECTIVE AND PATIENTS: Twenty-four pituitary adenomas from acromegalic patients (13 females, 11 males; age range 19-65 yr) were characterized for somatostatin receptor subtype 2A (sst(2A)), dopamine D(2) receptor (D(2)R), GH, and prolactin (PRL) expression by immunohistochemistry, and results correlated with the in vitro and in vivo hormone responses to octreotide and quinagolide.
  • In nine cases, GH and PRL content was further studied by immunoelectron microscopy.
  • Sst(2A) was scored as 2 in 13 cases, 1 in 10, and 0 in one; D(2)R was scored as 2 in 13 cases, 1 in nine, and 0 in 2; GH was 2 in 15 cases and 1 in nine; PRL was 2 in six cases, 1 in 13, and 0 in 5.
  • Sst(2A) was positively correlated with in vitro (P = 0.003) and in vivo (P = 0.006) percent GH suppression by octreotide and with the chronic suppression of IGF-I by somatostatin analogs (P =0.008).
  • D(2)R was positively correlated with in vitro percent GH (P =0.000) and PRL (P =0.005) suppression by quinagolide.
  • Electron microscopy revealed two pure somatotroph adenomas, five somatomammotrophs with a variable coexpression of GH and PRL in the same cells, and two tumors consisting of mixed cell types, which were less sensitive to quinagolide and octreotide.
  • CONCLUSION: Sst(2A) and D(2)R are frequently coexpressed in adenomas from acromegalic patients, and immunohistochemistry may be helpful in characterizing receptor expression in pituitary adenomas to select patients responsive to different treatments.
  • [MeSH-major] Adenoma / drug therapy. Aminoquinolines / therapeutic use. Dopamine Agonists / therapeutic use. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Octreotide / therapeutic use. Receptors, Dopamine D2 / analysis. Receptors, Somatostatin / analysis
  • [MeSH-minor] Adult. Female. Human Growth Hormone / blood. Humans. Immunohistochemistry. Male. Microscopy, Electron. Middle Aged. Prolactin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211974.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Dopamine Agonists; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin; 0 / somatostatin receptor sst2A; 12629-01-5 / Human Growth Hormone; 80Q9QWN15M / quinagolide; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


81. Jaffe CA: Clinically non-functioning pituitary adenoma. Pituitary; 2006;9(4):317-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinically non-functioning pituitary adenoma.
  • Non-functioning pituitary tumors are relatively common.
  • A large number of these tumors are incidentally found pituitary microadenomas (<1 cm) and are usually of no clinical importance.
  • Visual field defects are present in roughly 70% of patients with non-functioning macroadenoma at the time of diagnosis and the majority of these patients have at least growth deficiency and hypogonadism.
  • By immunocytochemistry, the large majority of these tumors are glycoprotein producing and less commonly they are non-functioning somatotroph, lactotroph or corticotoph adenomas.
  • Surgery improves visual defects in the majority of patients and a lesser number will recover pituitary function.
  • In the past, pituitary radiation was commonly administered following pituitary surgery; however the need for routine radiation has recently been reevaluated.
  • Close follow-up with surveillance pituitary scans should be performed after surgery and radiation therapy reserved for patients having significant tumor recurrence.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / therapy
  • [MeSH-minor] Algorithms. Antineoplastic Agents, Hormonal. Biomarkers / blood. Growth Disorders / etiology. Growth Disorders / therapy. Humans. Hypogonadism / etiology. Hypogonadism / therapy. Hypophysectomy. Hypopituitarism / etiology. Hypopituitarism / therapy. Practice Guidelines as Topic. Radiotherapy, Adjuvant. Recurrence. Treatment Outcome. Vision Disorders / etiology. Vision Disorders / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082898.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers
  • [Number-of-references] 17
  •  go-up   go-down


82. Thodou E, Argyrakos T, Kontogeorgos G: Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens); 2007 Jul-Sep;6(3):227-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas.
  • OBJECTIVE: Galectin-3 (Gal-3) belongs to the family of carbohydrate-binding proteins with high affinity for galactoside and is involved in many biological processes including cell growth and differentiation, cell adhesion, tumor progression, apoptosis and metastasis.
  • The aim of this study was to disclose differences in the expression of Gal-3 in silent and functioning corticotroph pituitary adenomas.
  • DESIGN: We examined 30 pituitary adenomas (19 functioning corticotroph, 11 silent corticotroph adenomas).
  • Two prolactinomas and 2 functioning somatotroph adenomas served as positive controls.
  • The independent variables t-test was used for comparison of the mean expression of Gal-3 in the two different corticotroph adenoma subgroups.
  • RESULTS: Eighteen of the functioning corticotroph adenomas (94.73%) were positive for Gal-3 with a cytoplasmic and focally membranous distribution; two cases also exhibited nuclear expression, whereas 9 of the silent corticotroph adenomas (81.81%) had zero or<1% expression of Gal-3 (p=0.001).
  • CONCLUSIONS: Gal-3 is highly expressed in functioning corticotroph adenomas of the pituitary gland, while silent adenomas exhibit very focal to null expression of Gal-3.
  • This observation can be used in the pathological diagnosis to separate functioning from silent corticotroph adenomas of the pituitary.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / metabolism. Galectin 3 / metabolism
  • [MeSH-minor] Humans. Immunohistochemistry. Pituitary Gland / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724007.001).
  • [ISSN] 1109-3099
  • [Journal-full-title] Hormones (Athens, Greece)
  • [ISO-abbreviation] Hormones (Athens)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


83. DiGiovanni R, Serra S, Ezzat S, Asa SL: AIP Mutations are not identified in patients with sporadic pituitary adenomas. Endocr Pathol; 2007;18(2):76-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIP Mutations are not identified in patients with sporadic pituitary adenomas.
  • The pathogenesis of pituitary adenomas remains a subject of interest.
  • Recently, mutations in the aryl hydrocarbon receptor-interacting protein (AIP) were identified as germline events leading to pituitary tumor predisposition in Finnish and Italian families with familial growth hormone-secreting pituitary adenomas and acromegaly.
  • We examined the frequency of AIP mutations in pituitary tumors and blood of Canadian patients with sporadic pituitary somatotroph adenomas and sporadic pituitary adenomas of other types.
  • Genomic DNA was extracted from pituitary tumors and white blood cells obtained from peripheral blood.
  • AIP mutations were not detected as germline events in blood or as somatic alterations in tumors of 66 patients with pituitary adenomas.
  • These included 50 acromegalics and 16 patients with other types of pituitary tumor.
  • Our results indicate that mutations in AIP are not identified in sporadic pituitary adenomas of Canadian patients.
  • This rare mechanism of pituitary tumorigenesis appears to be unique to the initial Finnish and Italian families described.
  • [MeSH-major] Adenoma / metabolism. Pituitary Neoplasms / metabolism. Proteins / metabolism
  • [MeSH-minor] Acromegaly / etiology. Canada / epidemiology. Cohort Studies. DNA / biosynthesis. DNA / genetics. DNA, Neoplasm / genetics. Exons / genetics. Gene Frequency. Germ-Line Mutation. Humans. Intracellular Signaling Peptides and Proteins

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916996.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proteins; 0 / aryl hydrocarbon receptor-interacting protein; 9007-49-2 / DNA
  •  go-up   go-down


84. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, Degli Uberti EC: Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab; 2010 Feb;95(2):968-76
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
  • CONTEXT: Pituitary adenomas can cause specific syndromes due to hormone excess and/or determine sellar mass symptoms.
  • Pituitary cell growth can sometimes be influenced by medical therapy, such as for somatotroph adenomas treated with somatostatin analogs or prolactinomas treated with dopaminergic drugs.
  • However, nonfunctioning pituitary adenomas (NFAs) are still orphans of medical therapy.
  • Cell viability and apoptosis were evaluated after 48 h, and vascular endothelial growth factor (VEGF) secretion was assessed after an 8-h incubation.
  • RESULTS: In 28 cultures (70%), Everolimus significantly reduced cell viability (by approximately 40%; P < 0.05 vs. control), promoted apoptosis (+30%; P < 0.05 vs. control), inhibited p70S6K activity (-20%), and blocked IGF-I proliferative and antiapoptotic effects.
  • CONCLUSIONS: Everolimus reduced NFA cell viability by inducing apoptosis, with a mechanism likely involving IGF-I signaling but not VEGF secretion, suggesting that it might represent a possible medical treatment of invasive/recurrent NFAs.
  • [MeSH-major] Adenoma / drug therapy. Immunosuppressive Agents / pharmacology. Pituitary Neoplasms / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Aged. Apoptosis / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Ergolines / pharmacology. Everolimus. Female. Humans. Male. Middle Aged. Receptors, Somatostatin / physiology. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Somatostatin / analogs & derivatives. Somatostatin / pharmacology. Vascular Endothelial Growth Factor A / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19965918.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ergolines; 0 / Immunosuppressive Agents; 0 / Receptors, Somatostatin; 0 / Vascular Endothelial Growth Factor A; 0 / somatostatin receptor 2; 51110-01-1 / Somatostatin; 98H1T17066 / pasireotide; 9HW64Q8G6G / Everolimus; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; LL60K9J05T / cabergoline; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


85. El-Bilbeisi H, Ghannam M, Nimri CF, Ahmad AT: Craniopharyngioma in a patient with acromegaly due to a pituitary macroadenoma. Ann Saudi Med; 2010 Nov-Dec;30(6):485-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniopharyngioma in a patient with acromegaly due to a pituitary macroadenoma.
  • We present the first reported case of a craniopharyngioma as a second primary tumor in a patient with acromegaly due to a growth hormone (GH)-secreting pituitary adenoma.
  • The patient was lost for follow-up for 18 years after trans-sphenoidal pituitary surgery for a GH-secreting pituitary adenoma.
  • She presented with headaches and decreased visual acuity, and showed unsuppressed GH in an oral glucose load test with high IGF-1 levels.
  • Biopsy of the mass confirmed the diagnosis of a craniopharyngioma.
  • We stress the need for close follow-up of patients with acromegaly with adequate control of GH and IGF-1 levels.
  • [MeSH-major] Acromegaly / etiology. Adenoma / pathology. Craniopharyngioma / pathology. Growth Hormone / secretion. Neoplasms, Second Primary / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1978 May;64(5):874-82 [206142.001]
  • [Cites] Pituitary. 2008;11(3):317-23 [17917812.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):43-54 [6243140.001]
  • [Cites] Clin Endocrinol (Oxf). 1980 Jan;12(1):71-9 [7379316.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1983;399(1):49-59 [6299000.001]
  • [Cites] Neurosurgery. 1986 Aug;19(2):267-70 [3748357.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1986 Nov;49(11):1305-7 [3794737.001]
  • [Cites] Neurosurgery. 1987 Sep;21(3):371-7 [3670583.001]
  • [Cites] Acta Med Scand. 1988;223(4):327-35 [3369313.001]
  • [Cites] Surg Neurol. 1989 May;31(5):381-6 [2711312.001]
  • [Cites] Ulster Med J. 1990 Apr;59(1):55-62 [2349750.001]
  • [Cites] Endocr Rev. 1995 Apr;16(2):143-63 [7540132.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1141-4 [9334728.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] J Pathol Bacteriol. 1955 Jan-Apr;69(1-2):141-5 [13243181.001]
  • [Cites] Arch Pathol. 1960 Sep;70:293-9 [13850582.001]
  • [Cites] Pituitary. 2004;7(1):39-44 [15638297.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4674-80 [16000560.001]
  • [Cites] Rev Endocr Metab Disord. 2008 Mar;9(1):41-58 [18157698.001]
  • [Cites] Postgrad Med J. 2000 Aug;76(898):513, 519-21 [10908388.001]
  • [Cites] Growth Horm IGF Res. 2000 Apr;10 Suppl A:S12-3 [10984274.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):2935-41 [11443146.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1886-94 [11576845.001]
  • [Cites] Br J Ophthalmol. 1975 Dec;59(12):689-95 [766825.001]
  • [Cites] Clin Endocrinol (Oxf). 1976 Sep;5(5):503-13 [991433.001]
  • [Cites] Clin Endocrinol (Oxf). 1979 Jan;10(1):61-7 [219974.001]
  • (PMID = 20864785.001).
  • [ISSN] 0975-4466
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  • [Other-IDs] NLM/ PMC2994169
  •  go-up   go-down


86. Gondim JA, Ferraz T, Mota I, Studart D, Almeida JP, Gomes E, Schops M: Outcome of surgical intrasellar growth hormone tumor performed by a pituitary specialist surgeon in a developing country. Surg Neurol; 2009 Jul;72(1):15-9; discussion 19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of surgical intrasellar growth hormone tumor performed by a pituitary specialist surgeon in a developing country.
  • BACKGROUND: Acromegaly is an excessive GH secretion, which in most cases, is caused by a pituitary GH-secreting adenoma.
  • Traditional treatment of acromegaly consists of surgery, drug therapy, and eventually radiotherapy.
  • The aim of this retrospective study is to evaluate the results of transsphenoidal endoscopic surgery in a group of patients with intrasellar GH adenoma who were operated by a pituitary specialist surgeon.
  • METHODS: We have analyzed data from 33 patients with intrasellar GH tumor who had been referred to the neuroendocrine department of the HGF, Brazil.
  • The patients underwent a transsphenoidal endoscopic adenomectomy for acromegaly between 2000 and 2005.
  • RESULTS: All 33 patients had intrasellar adenoma, 84.84% of patients achieved remission by surgery.
  • Five patients still had the disease and refused a second surgery.
  • A treatment with octreotide was started for these 5 patients and resulted in an adequate control of GH and IGF-1 levels.
  • CONCLUSION: Our patients, with intrasellar GH tumor, operated by a pituitary specialist neurosurgeon had remission rates approaching those obtained by most specialized neurosurgical centers worldwide.
  • [MeSH-major] Adenoma / surgery. Endoscopy / statistics & numerical data. Growth Hormone-Secreting Pituitary Adenoma / surgery. Neurosurgical Procedures / statistics & numerical data. Sella Turcica / surgery. Sphenoid Bone / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440607.001).
  • [ISSN] 1879-3339
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


87. Mercado M, Galeana M: [Pharmacological treatment of acromegaly]. Gac Med Mex; 2006 Jul-Aug;142(4):327-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacological treatment of acromegaly].
  • [Transliterated title] Tratamiento farmacológico de la acromegalia.
  • Acromegaly is an endocrine disorder usually due to a growth hormone (GH)-secreting pituitary adenoma.
  • This deforming disease is associated with several metabolic abnormalities and results in an elevated cardiovascular mortality.
  • Pituitary transsesphenoidal surgery has been considered the treatment of choice, however, even in the most experienced hands this procedure succeeds in curing only 50 to 60% of the patients.
  • Therefore, close to 50% of patients require an adjunctive form of treatment such as radiation therapy or the use of diverse medications that modulate GH secretion (somatostatin analogues) or action (GH receptor antagonists).
  • [MeSH-major] Acromegaly / drug therapy
  • [MeSH-minor] Humans. Receptors, Somatotropin / antagonists & inhibitors. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022308.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Receptors, Somatotropin; 51110-01-1 / Somatostatin
  • [Number-of-references] 66
  •  go-up   go-down


88. Manavela MP, Juri A, Danilowicz K, Bruno OD: [Therapeutic management in 154 acromegalic patients]. Medicina (B Aires); 2010;70(4):328-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acromegaly is a chronic, invalidating disease due in over 95% of cases to a growth hormone (GH) secreting pituitary adenoma.
  • Its clinical manifestations are associated to local complications related to the tumor growth and/or to the metabolic consequences of GH excess.
  • In only 14.0% of acromegalics drug therapy with dopaminergic agents was effective in controlling the disease.
  • In summary, multimodal therapy of acromegaly can lead to a global safe control of the disease in 55.2% of the cases.
  • [MeSH-major] Acromegaly / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Human Growth Hormone / metabolism. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20679052.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


89. Pertuit M, Barlier A, Enjalbert A, Gérard C: Signalling pathway alterations in pituitary adenomas: involvement of Gsalpha, cAMP and mitogen-activated protein kinases. J Neuroendocrinol; 2009 Nov;21(11):869-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signalling pathway alterations in pituitary adenomas: involvement of Gsalpha, cAMP and mitogen-activated protein kinases.
  • Despite extensive research on sporadic pituitary adenomas, it is not yet possible to assign one protein alteration to one specific type of pituitary adenomas.
  • Nevertheless, alterations of the cAMP pathway appear to be molecular hallmarks of most growth hormone (GH)-secreting adenomas.
  • In this review, we summarise the literature regarding signalling alterations observed in GH-secreting adenomas.
  • In the light of results obtained on human somatotroph adenoma cells in primary culture and on models of murine somatotroph cell lines, we postulate a crucial role for ERK1/2 in GH-secreting adenomas downstream of cAMP pathway alterations that might impact the tumoural phenotype.
  • [MeSH-major] Adenoma / metabolism. Cyclic AMP / metabolism. GTP-Binding Protein alpha Subunits, Gs / metabolism. Mitogen-Activated Protein Kinases / metabolism. Pituitary Neoplasms / metabolism. Signal Transduction
  • [MeSH-minor] Growth Hormone / secretion. Humans

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732293.001).
  • [ISSN] 1365-2826
  • [Journal-full-title] Journal of neuroendocrinology
  • [ISO-abbreviation] J. Neuroendocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone; E0399OZS9N / Cyclic AMP; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  • [Number-of-references] 95
  •  go-up   go-down


90. Popovic V: Are there alternative tests for diagnosis of acromegaly? J Endocrinol Invest; 2005;28(11 Suppl International):73-4
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there alternative tests for diagnosis of acromegaly?
  • In acromegaly, clinical features are of the utmost importance, and biochemical confirmation is rarely difficult.
  • However, some clinically manifest acromegalics have subtle abnormalities in GH secretion resulting in post-glucose GH nadir in the designated "normal" range with high IGF-I levels.
  • Clinical decision may be based on the probability of the disease and elevated IGF-I levels.
  • The TRH test or the frequent GH sampling test may help confirm acromegaly but on their own have no diagnostic advantage.
  • A TRH-GH response is not specific to acromegaly, while frequent sampling is not practical.
  • Post-treatment assessment of the disease activity and definition of acromegaly cure, by measuring GH secretion, remain problematic.
  • IGF-I levels seem to differentiate normality less clearly and discordance of GH and IGF-I results is frequent.
  • Post-treatment probability for residual disease activity should include more clinical parameters such as insulin sensitivity, leptin and echocardiography.
  • Furthermore, with efforts to achieve tight biochemical control of the disease it is foreseeable that a proportion of patients may be rendered GH deficient, requiring stimulatory testing.
  • Acromegaly is a disfiguring and disabling illness, in which by definition, the disorder is caused by a pituitary GH-secreting adenoma resulting in high circulating levels of GH and IGF-I.
  • The clinical features of acromegaly include those of GH and IGF-I on tissues and the effects of the pituitary tumor itself.
  • There is no single cut-off value for GH with perfect discrimination between acromegaly and normality.
  • The recommended post-glucose GH nadir value of 1 microg/l is now considered to be inappropriately high, and measurement of IGF-I levels although extremely valuable has its limitations.
  • Furthermore, some acromegalics may have subtle abnormalities in GH secretion, resulting in post-glucose GH nadir in the designated "normal" range with elevated IGF-I levels.
  • [MeSH-major] Acromegaly / diagnosis
  • [MeSH-minor] Glucose Tolerance Test. Human Growth Hormone / blood. Human Growth Hormone / secretion. Humans. Insulin-Like Growth Factor I / analysis. Pituitary Neoplasms. Thyrotropin-Releasing Hormone

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625850.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 5Y5F15120W / Thyrotropin-Releasing Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  • [Number-of-references] 11
  •  go-up   go-down


91. Lau SL, McGrath S, Evain-Brion D, Smith R: Clinical and biochemical improvement in acromegaly during pregnancy. J Endocrinol Invest; 2008 Mar;31(3):255-61
MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biochemical improvement in acromegaly during pregnancy.
  • Numerous case reports of pregnancy in acromegaly exist, however detailed descriptions of changes in placental and pituitary GH and IGF-I throughout gestation are rare.
  • A 19-yr-old female presented to this institution with signs and symptoms of a GH-secreting pituitary adenoma.
  • Following transphenoidal hypophysectomy, she had 3 unplanned pregnancies, despite ongoing active disease.
  • This was despite increasing placental GH levels, and was not consistent with previous reports in the literature.
  • Further surgical and medical therapies for acromegaly failed to normalize nonpregnant GH or IGF-I levels in this woman.
  • Estrogen is known to alter GH signaling via its interaction with Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathways.
  • [MeSH-major] Acromegaly / physiopathology. Pregnancy Complications / physiopathology
  • [MeSH-minor] Adult. Female. Human Growth Hormone / analysis. Human Growth Hormone / blood. Human Growth Hormone / secretion. Humans. Hypophysectomy. Insulin-Like Growth Factor I / analysis. Magnetic Resonance Imaging. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery. Placenta / chemistry. Pregnancy. Pregnancy Complications, Neoplastic / physiopathology. Pregnancy Outcome. Reoperation

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18401209.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


92. Manahan MA, Dackiw AP, Ball DW, Zeiger MA: Unusual case of metastatic neuroendocrine tumor. Endocr Pract; 2007 Jan-Feb;13(1):72-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report a rare case of metastatic growth hormone (GH)-secreting pituitary carcinoma causing acromegaly.
  • RESULTS: A 68-year-old woman presented with persistent acromegaly after treatment for a GH-secreting pituitary adenoma.
  • After operative treatment including total thyroidectomy, subtotal parathyroidectomy, partial thymectomy, and right modified radical neck dissection, the patient's symptoms diminished, and her GH levels approached the normal range.
  • Surgical pathology findings were consistent with a GH-secreting pituitary carcinoma metastatic to the cervical lymph nodes, multinodular thyroid hyperplasia with a focus of papillary microcarcinoma, and parathyroid hyperplasia.
  • CONCLUSION: Overall, pituitary carcinomas are extremely rare.
  • To date, about 100 cases have been reported in the world's literature, and of these, only 19 cases originated from GH-secreting cells.
  • Our examination of the symptoms, signs, diagnosis, and treatment of our patient, in comparison with the previously reported cases, should enhance awareness of this unusual disease process.
  • [MeSH-major] Adenoma / pathology. Growth Hormone-Secreting Pituitary Adenoma / pathology. Parathyroid Neoplasms / secondary. Thymus Neoplasms / secondary. Thyroid Neoplasms / secondary
  • [MeSH-minor] Acromegaly / etiology. Aged. Female. Humans. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17360306.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


93. Acunzo J, Thirion S, Roche C, Saveanu A, Gunz G, Germanetti AL, Couderc B, Cohen R, Figarella-Branger D, Dufour H, Brue T, Enjalbert A, Barlier A: Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res; 2008 Dec 15;68(24):10163-70
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.
  • In human somatotroph adenomas, growth hormone (GH) hypersecretion can be inhibited by somatostatin analogues such as octreotide.
  • Unfortunately, serum GH levels reach normal values in only 60% of treated patients.
  • In this present study, the sst2 gene was transferred by an adenoviral vector (Ad-sst2) in human somatotroph (n = 7) and lactotroph (n = 2) adenomas in vitro.
  • Ten days after infection at 20 multiplicity of infection (MOI), sst2 gene transfer decreased cell viability from 19% to 90% by caspase-dependent apoptosis.
  • At low viral doses (5 MOI), Ad-sst2 decreased GH or prolactin (PRL) basal secretion and mRNA expression.
  • Somatotroph tumors were classified in three groups according to their octreotide sensitivity.
  • Four days after infection by 5 MOI Ad-sst2, the maximal GH suppression by octreotide increased from 31% to 57% in the octreotide partially resistant group and from 0% to 27% in the resistant ones.
  • In the octreotide-sensitive group, EC(50) values significantly decreased from 1.3 x 10(-11) to 6.6 x 10(-13) mol/L without improving maximal GH suppression.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Human Growth Hormone / secretion. Octreotide / pharmacology. Pituitary Neoplasms / drug therapy. Prolactin / secretion. Prolactinoma / drug therapy
  • [MeSH-minor] Adenoviridae / genetics. Cell Survival / physiology. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Somatostatin / biosynthesis. Receptors, Somatostatin / genetics. Transduction, Genetic. Transgenes

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Guide to Pharmacology. gene/protein/disease-specific - sst2 receptor - data and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074883.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


94. Segal-Lieberman G, Rubinfeld H, Glick M, Kronfeld-Schor N, Shimon I: Melanin-concentrating hormone stimulates human growth hormone secretion: a novel effect of MCH on the hypothalamic-pituitary axis. Am J Physiol Endocrinol Metab; 2006 May;290(5):E982-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanin-concentrating hormone stimulates human growth hormone secretion: a novel effect of MCH on the hypothalamic-pituitary axis.
  • Melanin-concentrating hormone (MCH), a 19-amino acid orexigenic (appetite-stimulating) hypothalamic peptide, is an important regulator of energy homeostasis.
  • Because pituitary hormones such as growth hormone (GH), ACTH, and thyroid-stimulating hormone affect body weight and composition, appetite, insulin sensitivity, and lipoprotein metabolism, we investigated whether MCH exerts direct effects on the human pituitary to regulate energy balance using dispersed human fetal pituitaries (21-22 wk gestation) and cultured GH-secreting adenomas.
  • We found that MCH receptor-1 (MCH-R1), but not MCH receptor-2, is expressed in both normal (fetal and adult) human pituitary tissues and in GH cell adenomas.
  • MCH (10 nM) stimulated GH release from human fetal pituitary cultures by up to 62% during a 4-h incubation (P < 0.05).
  • Interestingly, neuropeptide EI (10 nM), which is also cleaved from ppMCH, increased human GH secretion by up to 124% in fetal pituitaries.
  • A milder, albeit significant, induction of GH secretion by MCH (20%) was seen in cultured GH-secreting pituitary adenomas.
  • A comparable stimulation of GH secretion was seen when cultured mouse pituitary cells were treated with MCH.
  • Treatment of cultured GH adenoma cells with MCH (100 nM) induced extracellular signal-regulated kinases 1 and 2 phosphorylation, suggesting activation of MCH-R1.
  • In aggregate, these data suggest that MCH may regulate pituitary GH secretion and imply a potential cross-talk mechanism between appetite-regulating neuropeptides and pituitary hormones.
  • [MeSH-major] Human Growth Hormone / secretion. Hypothalamic Hormones / pharmacology. Hypothalamo-Hypophyseal System / drug effects. Melanins / pharmacology. Pituitary Hormones / pharmacology
  • [MeSH-minor] Animals. Cells, Cultured. Fetus. Gene Expression / genetics. Growth Hormone-Releasing Hormone / pharmacology. Humans. Mice. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Oligopeptides / pharmacology. Phosphorylation / drug effects. Pituitary Gland / cytology. Pituitary Gland / metabolism. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology. Receptors, Somatostatin / genetics. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603725.001).
  • [ISSN] 0193-1849
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypothalamic Hormones; 0 / MCHR1 protein, human; 0 / Melanins; 0 / Oligopeptides; 0 / Pituitary Hormones; 0 / Receptors, Somatostatin; 0 / neuropeptide EI; 12629-01-5 / Human Growth Hormone; 67382-96-1 / melanin-concentrating hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


95. Ikeda H, Takayasu S: A growth hormone-secreting adenoma with incomplete nerve bundle formation. Neuropathology; 2008 Jun;28(3):317-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A growth hormone-secreting adenoma with incomplete nerve bundle formation.
  • We present a unique case of an adenoma secreting growth hormone (GH), showing incomplete nerve bundle formation without ganglion cells.
  • A 47-year-old man presenting with acromegaly was revealed to have high serum GH and IGF-1 levels.
  • Histology revealed an unusual pituitary adenoma containing many nerve bundle-like structures.
  • Adenoma cells with ovoid or round hyperchromatic nuclei and eosinophilic cytoplasms lacked the typical features of ganglion cells.
  • By immunohistochemistry, many adenoma cells were positive for GH, prolactin, thyrotropin beta, synaptophysin and chromogranin.
  • Fibrous bodies revealed by keratin immunostaining were found only in adenoma cells.
  • Scattered star-shaped adenoma cells showed the same immunoreactivity as folliculo-satellite cells.
  • Adenoma cells, but not the bundle-like structures, were also positive for Pit-1.
  • Our case is the first GH-secreting pituitary adenoma showing incomplete nerve bundle differentiation and lacking mature ganglion cells.
  • [MeSH-major] Adenoma / pathology. Growth Hormone-Secreting Pituitary Adenoma / pathology. Neurons / pathology
  • [MeSH-minor] Acromegaly / etiology. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194142.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


96. Flitsch J, Lüdecke DK, Saeger W, Veit JA, Metternich FU: [Acromegaly-associated lesions of the nasal mucosa. Case report]. HNO; 2009 Aug;57(8):845-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acromegaly-associated lesions of the nasal mucosa. Case report].
  • Acromegaly is a rare disease caused by a growth-hormone-secreting pituitary adenoma.
  • Besides these "cosmetic" symptoms, the disease is associated with hypertension and diabetes mellitus, as well as with an increased risk for adenomas and carcinomas of the colon.
  • The average time span from first symptom to diagnosis is well over 6 years; a single determination of insulin-like growth factor 1 in serum can confirm the disease.
  • The treatment of choice remains surgical resection of the adenoma in suitable patients, whereas in extensive disease with invasion of surrounding tissue, drug therapy and/or radiotherapy may be necessary.
  • [MeSH-major] Acromegaly / complications. Acromegaly / surgery. Adenoma / etiology. Adenoma / surgery. Nasal Mucosa / surgery. Nose Neoplasms / etiology. Nose Neoplasms / surgery

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19557321.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


97. Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M: Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol; 2006 Mar;59(3):274-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas.
  • BACKGROUND: Somatostatin is a tetradecapeptide exerting inhibitory action on endocrine and exocrine cell secretion and proliferation.
  • Using immunohistochemistry, the expression of SST(1), SST(2A), SST(2B), SST(3), SST(4), and SST(5) was studied in tissue microarrays (TMAs), using a series of 90 human pituitary adenomas producing growth hormone and/or prolactin, including 30 of each somatotroph, lactotroph, and mixed somatotroph/lactotroph adenoma type.
  • SST(5) and SST(2A) were the predominant receptors, showing strong expression in high frequency in all three adenoma types.
  • Strong expression of SST(1) was higher in lactotroph adenomas than in other tumour types.
  • [MeSH-major] Adenoma / chemistry. Biomarkers, Tumor / analysis. Pituitary Neoplasms / chemistry. Receptors, Somatostatin / analysis
  • [MeSH-minor] Case-Control Studies. Female. Growth Hormone / secretion. Humans. Immunohistochemistry / methods. Membrane Proteins / analysis. Prolactinoma / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1987 Dec;65(6):1127-34 [2824549.001]
  • [Cites] Front Horm Res. 2004;32:235-52 [15281350.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):398-403 [8106629.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3455-9 [8012966.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):724-9 [7521350.001]
  • [Cites] Life Sci. 1995;56(5):333-42 [7530798.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1386-92 [7714115.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):427-42 [8521788.001]
  • [Cites] J Neuroendocrinol. 1996 Aug;8(8):605-10 [8866248.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):789-98 [9045884.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):530-7 [9052751.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):3011-8 [9284735.001]
  • [Cites] J Endocrinol Invest. 1997 Jun;20(6):348-67 [9294784.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2417-20 [9661621.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2997-3000 [9709982.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2047-52 [9748118.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):775-80 [10022452.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):1966-75 [10473073.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3268-76 [10487698.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):787-97 [11787852.001]
  • [Cites] Virchows Arch. 2002 May;440(5):461-75 [12021920.001]
  • [Cites] Surg Today. 2002;32(8):690-4 [12181718.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):28-47 [12588807.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3483-7 [10589762.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):781-92 [10690891.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7862-9 [10713101.001]
  • [Cites] Diagn Mol Pathol. 2000 Mar;9(1):47-57 [10718213.001]
  • [Cites] Lab Invest. 2000 Dec;80(12):1943-9 [11140706.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] Eur J Clin Invest. 2001 Mar;31(3):208-14 [11264647.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 May;54(5):641-9 [11380495.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 1;93(15):1141-6 [11481385.001]
  • [Cites] Gut. 2002 Jan;50(1):52-60 [11772967.001]
  • [Cites] N Engl J Med. 1983 Dec 15;309(24):1495-501 [6139753.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Aug;25(2):201-12 [2878748.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1577-85 [15070915.001]
  • [Cites] Neuroendocrinology. 2004 Mar;79(3):142-8 [15103227.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5969-77 [2168286.001]
  • (PMID = 16505278.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 3; 0 / somatostatin receptor 5; 0 / somatostatin receptor subtype-4; 9002-72-6 / Growth Hormone
  • [Other-IDs] NLM/ PMC1860351
  •  go-up   go-down


98. Nishioka H, Haraoka J: Biochemical cure of acromegaly after transsphenoidal surgery despite residual tumor on magnetic resonance imaging: case report. Neurol Med Chir (Tokyo); 2008 Jul;48(7):311-3
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical cure of acromegaly after transsphenoidal surgery despite residual tumor on magnetic resonance imaging: case report.
  • A 52-year-old acromegalic woman underwent transsphenoidal removal of a pituitary macroadenoma.
  • Postoperative magnetic resonance (MR) imaging demonstrated small residual tumor, but her acromegaly was "cured" using current strict criteria.
  • The histological diagnosis was somatotroph cell adenoma with fibrous bodies.
  • Biochemical cure may not reflect total removal of the tumor, particularly if the growth hormone secretory activity of the residual tumor is low.
  • Careful evaluation of postoperative MR imaging is always necessary to interpret surgical outcome, even if biochemical cure in acromegaly has been achieved.
  • [MeSH-major] Growth Hormone / blood. Growth Hormone-Secreting Pituitary Adenoma / surgery. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Neoplasm, Residual / diagnosis. Pituitary Neoplasms / surgery. Postoperative Complications / diagnosis. Sphenoid Sinus / surgery
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Middle Aged. Pituitary Function Tests. Pituitary Gland / pathology. Pituitary Gland / surgery

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654051.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


99. Hofstetter CP, Mannaa RH, Mubita L, Anand VK, Kennedy JW, Dehdashti AR, Schwartz TH: Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus; 2010 Oct;29(4):E6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
  • OBJECT: The aim of this study was to determine the preoperative predictors of the extent of resection and endocrinological remission following endonasal endoscopic removal of growth hormone (GH)-secreting pituitary adenomas.
  • Endocrinological remission was defined as normal insulin-like growth factor I (IGFI) serum levels and either a nadir GH level of < 0.4 ng/ml after an oral glucose load or a basal GH serum level < 1 ng/ml.
  • A smaller tumor volume and a postoperative reduction in GH serum levels were associated with a higher rate of biochemical cure (p < 0.05).
  • During a 23-month follow-up period 5 patients (21%) underwent Gamma Knife treatment of any residual disease to further reduce excess GH production.
  • CONCLUSIONS: A purely endoscopic endonasal transsphenoidal adenoma resection leads to a high rate of gross-total tumor resection and endocrinological remission in acromegalic patients, even those harboring macroadenomas with wide suprasellar extension.
  • [MeSH-major] Acromegaly / surgery. Adenoma / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Human Growth Hormone / secretion. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Endoscopy. Female. Humans. Insulin-Like Growth Factor I / analysis. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Postoperative Period. Preoperative Period. Remission Induction. Sphenoid Bone. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887131.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


100. Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J: Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab; 2009 Oct;23(5):555-74
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary tumours: acromegaly.
  • Excessive production of the growth hormone (GH) is responsible for acromegaly.
  • It is related to a pituitary GH-secreting adenoma in most cases.
  • The diagnosis is confirmed by an increased serum GH concentration, unsuppressible by an oral glucose load and by detection of increased levels of insulin-like growth factor-I (IGF-I).
  • Treatment is aimed at correcting (or preventing) tumour compression by excising the disease-causing lesion, and at reducing GH and IGF-I levels to normal values.
  • When surgery, the usual first-line treatment, fails to correct GH/IGF-I hypersecretion, medical treatment with somatostatin analogues and/or radiotherapy can be used.
  • The GH-receptor antagonist (pegvisomant) is helpful in patients who are resistant to somatostatin analogues.
  • Thanks to this multistep therapeutic strategy, adequate hormonal disease control is achieved in most cases, allowing a normal life expectancy.
  • [MeSH-major] Acromegaly / etiology. Adenoma / complications. Growth Hormone-Secreting Pituitary Adenoma / complications
  • [MeSH-minor] Carcinoma / diagnosis. Carcinoma / secretion. Carcinoma / therapy. Humans. Models, Biological. Professional Practice

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19945023.001).
  • [ISSN] 1878-1594
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 98
  •  go-up   go-down






Advertisement